[go: up one dir, main page]

WO2023129976A1 - Sel et formes solides de kétansérine - Google Patents

Sel et formes solides de kétansérine Download PDF

Info

Publication number
WO2023129976A1
WO2023129976A1 PCT/US2022/082488 US2022082488W WO2023129976A1 WO 2023129976 A1 WO2023129976 A1 WO 2023129976A1 US 2022082488 W US2022082488 W US 2022082488W WO 2023129976 A1 WO2023129976 A1 WO 2023129976A1
Authority
WO
WIPO (PCT)
Prior art keywords
pattern
ketanserin
solid form
xrpd
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/082488
Other languages
English (en)
Inventor
Matthew Duncton
Samuel CLARK
Grace Jung
Gary Goodson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terran Biosciences Inc
Original Assignee
Terran Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terran Biosciences Inc filed Critical Terran Biosciences Inc
Publication of WO2023129976A1 publication Critical patent/WO2023129976A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/10—Succinic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/145—Maleic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/265—Citric acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present disclosure relates to forms of ketanserin, including solid forms of ketanserin free base, salts of ketanserin and solid forms thereof, including crystalline forms of the compound and salts thereof, as well as polymorphs of the solid forms.
  • Ketanserin is a selective 5-HT2 serotonin receptor antagonist with weak adrenergic receptor blocking properties. Ketanserin also blocks 5-HT receptors on platelets, antagonizing platelet aggregation promoted by serotonin.
  • ketanserin including solid forms of ketanserin free form, salts of ketanserin and solid forms thereof, including crystalline forms of the compound and salts thereof, as well as polymorphs of the solid forms.
  • the solid form of ketanserin is a form of the free base form of the compound, such as polymorph of the free base form of the compound.
  • the solid form of ketanserin is a salt, and may be a polymorph of the salt.
  • Also disclosed herein are methods for using the forms of ketanserin such as a method for using form of ketanserin as a 5-HT2 serotonin receptor modulator, including, without limitation the use of ketanserin as a monotherapy or in combination with another agent, such as psychedelic agent.
  • Figure 1 provides an XRPD pattern of free base form Pattern A of ketanserin.
  • Figure 2 provides an XRPD pattern of free base form Pattern B.
  • Figure 3 provides an XRPD pattern of ketanserin hydrochloride Pattern A.
  • Figure 4 provides an XRPD pattern of ketanserin sulfate Pattern A.
  • Figure 5 provides an XRPD pattern of ketanserin fumarate Pattern A.
  • Figure 6 provides an XRPD pattern of ketanserin fumarate Pattern B.
  • Figure 7 provides an XRPD pattern of ketanserin citrate Pattern A.
  • Figure 8 provides an XRPD pattern of ketanserin maleate Pattern A.
  • Figure 9 provides an XRPD pattern of ketanserin p-tosylate Pattern A.
  • Figure 10 provides an XRPD pattern of ketanserin esylate Pattern A.
  • Figure 11 provides an XRPD pattern of ketanserin esylate Pattern B.
  • Figure 12 provides an XRPD pattern of ketanserin esylate Pattern C.
  • Figure 13 provides an XRPD pattern of ketanserin mesylate Pattern A.
  • Figure 14 provides an XRPD pattern of ketanserin mesylate Pattern B.
  • Figure 15 provides an XRPD pattern of ketanserin besylate Pattern A.
  • Figure 16 provides an XRPD pattern of ketanserin besylate Pattern B.
  • Figure 17 provides an XRPD pattern of ketanserin hydrochloride Pattern B.
  • Figure 18 provides an XRPD pattern of ketanserin L-tartrate Pattern A.
  • Figure 19 provides an XRPD pattern of ketanserin L-malate Pattern A.
  • Figure 20 provides an XRPD pattern of ketanserin succinate Pattern A.
  • Figure 21 provides an XRPD pattern of ketanserin succinate Pattern B.
  • Figure 22 provides an XRPD pattern of ketanserin succinate Pattern C.
  • Figure 23 provides an XRPD pattern of ketanserin succinate Pattern D.
  • Figure 24 provides an XRPD pattern of ketanserin succinate Pattern E.
  • Figure 25 provides an XRPD pattern of ketanserin succinate Pattern F.
  • Figure 26 provides an XRPD pattern of ketanserin succinate Pattern G.
  • Figure 27 provides an XRPD pattern of ketanserin succinate Pattern H.
  • Figure 28 provides an XRPD pattern of ketanserin L-tartrate Group 4.
  • Figure 29 provides an XRPD pattern of ketanserin L-tartrate Pattern C.
  • Figure 30 provides an XRPD pattern of ketanserin L-tartrate Group 3.
  • Figure 31 provides an XRPD pattern of ketanserin L-tartrate Pattern E.
  • Figure 32 provides an XRPD pattern of ketanserin L-tartrate Pattern F.
  • Figure 33 provides an XRPD pattern of ketanserin L-tartrate Pattern G.
  • Figure 34 provides an XRPD pattern of ketanserin L-tartrate Pattern H.
  • Figure 35 provides an XRPD pattern of ketanserin L-tartrate Group 1.
  • Figure 36 provides an XRPD pattern of ketanserin L-tartrate Pattern I.
  • Figure 37 provides an XRPD pattern of ketanserin L-tartrate Pattern J.
  • Figure 38 provides an XRPD pattern of ketanserin L-tartrate Group 2.
  • Figure 39 provides an XRPD pattern of ketanserin L-tartrate of Group 5.
  • Figure 40 provides an XRPD pattern of ketanserin L-tartrate Pattern L.
  • Figure 41 provides an XRPD pattern of ketanserin L-tartrate Pattern M.
  • Figure 42 provides an XRPD pattern of ketanserin L-tartrate Pattern N.
  • Figure 43 provides an XRPD pattern of ketanserin L-tartrate Pattern O.
  • Figure 44 provides an XRPD pattern of ketanserin free base form Pattern A.
  • Figure 45 provides an XRPD pattern of ketanserin free base form Pattern B.
  • Figure 46 provides an XRPD pattern of ketanserin free base form Pattern C.
  • Figure 47 provides an XRPD pattern of ketanserin malate Pattern B.
  • Figure 48 provides an XRPD pattern of ketanserin malate Pattern C*.
  • Figure 49 provides an XRPD pattern of ketanserin malate Pattern D.
  • Figure 50 provides an XRPD pattern of ketanserin malate Pattern E.
  • Figure 51 provides a DSC thermogram of ketanserin maleate Pattern B.
  • Figure 52 provides a proton NMR spectrum of ketanserin maleate Pattern B.
  • Figure 53 provides an XRPD diffractogram of crystalline ketanserin L-tartrate having Pattern P.
  • Figure 54 provides an XRPD diffractogram of crystalline ketanserin L-tartrate having Pattern R.
  • Figure 55 provides an XRPD diffractogram of crystalline ketanserin L-tartrate having Pattern S.
  • Figure 56 provides an XRPD diffractogram of crystalline ketanserin L-tartrate having Pattern B.
  • Figure 57 provides an XRPD diffractogram of crystalline ketanserin L-tartrate having Pattern K.
  • Figure 58 provides an XRPD diffractogram of crystalline ketanserin L-tartrate having Pattern D.
  • Figure 59 provides an XRPD diffractogram of crystalline ketanserin- L-tartrate having Pattern Q.
  • Figure 60 provides an XRPD diffractogram of crystalline ketanserin L-tartrate having Pattern T.
  • Figure 61 provides an XRPD diffractogram of crystalline ketanserin L-tartrate having Pattern A.
  • Figure 62 provides an XRPD diffractogram of crystalline ketanserin L-tartrate in the form of Group 1.
  • Figure 63 provides an XRPD diffractogram of crystalline ketanserin of free base form Pattern A.
  • Figure 64 provides an XRPD diffractogram of crystalline ketanserin of free base form Pattern D.
  • Figure 65 provides an XRPD diffractogram of ketanserin L-malate Pattern A.
  • Figure 66 provides an XRPD diffractogram of ketanserin L-malate Pattern C.
  • Figure 67 illustrates the effect of ketanserin on average cumulative head twitches induced by LSD.
  • Figure 68 provides a bar chart of head twitches occurring before and after control or antagonist administration (left bar in each pair is LSD/vehicle control and right is LSD/ketanserin).
  • Figure 69 illustrates the effect of ketanserin on average cumulative head twitches induced by psilocybin.
  • Figure 70 provides a bar chart of head twitches occurring before and after control or antagonist administration (left bar in each pair is psilocybin/vehicle control and right is psilocybin/ketanserin).
  • Figure 71 illustrates functional whole-brain network partition. Modified and reprinted from Ji et al., NeuroImage (2019).
  • Figure 72 illustrates dense Global Brain Connectivity (GBC) maps showing the difference in GBC (AGBC) for the ketanserin (Ket) + LSD-treated subjects vs placebo (Pla) + Pla contrast at the early time point (75 -minute) after treatment.
  • GBC Global Brain Connectivity
  • Figure 73 illustrates dense GBC maps showing the difference in GBC (AGBC) for the placebo + LSD-treated subjects vs placebo + placebo contrast at the early time point (75-minute) after treatment.
  • Figure 74 illustrates dense GBC maps showing the difference in GBC (AGBC) for the ketanserin + LSD-treated subjects vs placebo + placebo contrast at the late time point (300-minute) after treatment.
  • Figure 75 illustrates dense GBC maps showing the difference in GBC (AGBC) for the placebo + LSD-treated subjects vs placebo + placebo contrast at the late time point (300-minute) after treatment.
  • Figure 76 illustrates a collection of panels showing early session time point (75-minute) results and late session time point (300-minute) results for the difference in Functional Connectivity (AFC) between the test conditions.
  • the left of each row indicates the test conditions and the top of each column indicates the time points.
  • Positive and negative contrasts are rendered, respectively, in red and blue hues. Nodes along the edges indicate (cortical and subcortical) parcels of the CAP-NP parcellation.
  • Figure 77 illustrates related effects of Ket+LSD and Pla+LSD on parcels’ GBC values.
  • Panels show 2d-histograms across parcels, indicating how pretreatment+treatment effects for Ket+LSD and Pla+LSD (relative to the placebo+placebo condition) were related.
  • the late time point (right panel; 300 minutes)
  • Table 181 also shows correlations between GBC changes in parcels induced by Pla+LSD and Ket+LSD (relative to Pla+Pla).
  • Figure 78 illustrates related effects of Ket+LSD and Pla+LSD on parcels’ Functional Connectivity (FC) values.
  • Panels show 2d-histograms across connections between parcels, indicating how pretreatment+treatment effects for Ket+LSD and Pla+LSD (relative to the placebo+placebo condition) are related.
  • At the early time point left panel; 75 minutes
  • effects between the two conditions were weakly correlated
  • at the late time point (right panel; 300 minutes) a strong positive correlation was observed.
  • Table 182 also shows correlations between FC changes in parcels induced by Pla+LSD and Ket+LSD (relative to Pla+Pla).
  • Figure 79 illustrates AGBC confidence intervals for the early time point. Confidence intervals were calculated assuming a t-distribution. The CAP-NP network to which a parcel belongs is indicated by labels on the row. Additionally, a confidence interval was plotted in a desaturated (light) shade of grayscale if the FDR-BH corrected p-value is > 0.05. Top row indicates Pla+LSD vs Pla+Pla. Middle row indicates Ket+LSD vs Pla+Pla. Bottom row indicates Pla+LSD vs Ket+LSD.
  • Figure 80 illustrates AGBC confidence intervals for the late time point. Confidence intervals were calculated assuming a t-distribution. The CAP-NP network to which a parcel belongs is indicated by labels on the row. Additionally, a confidence interval was plotted in a desaturated (light) shade of grayscale if the FDR-BH corrected p-value is > 0.05. Top row indicates Pla+LSD vs Pla+Pla. Middle row indicates Ket+LSD vs Pla+Pla. Bottom row indicates Pla+LSD vs Ket+LSD.
  • Figure 81 illustrates network FC contrasts. For each pair of networks, all connection contrasts (i.e. AFC values) between these two networks were averaged resulting in a network x network FC contrast matrix. Networks are defined in the CAP-NP atlas. The contrasts shown here are average contrasts for a given network pair (left column of panels: 75 minutes after treatment; right column of panels: 300 minutes after treatment).
  • Figure 82 illustrates the time course of subjective drug effects for the labeled subject groups.
  • Five Dimension Altered States of Consciousness Questionnaire short version scores were assessed at 180, 250, and 360 minutes after second drug administration for the means across scales, and the scale scores for Pla, LSD, and Ket+LSD conditions. Scores are expressed as percent of the scale maximum. Data are expressed as means +/- the standard error of the mean (SEM).
  • SEM standard error of the mean
  • the first graph indicates the mean across scales.
  • the second and third graphs indicates that the subjective LSD effects were still intense and high above placebo at 360 minutes.
  • the fourth graph indicates that at no time point is there a significant presentation of self-reported altered states of consciousness in the Ket+LSD test subject group compared with the other graphs.
  • This figure is reprinted from eLife Preller 2018. (Preller et al. eLife. 2018 Oct 25;7:e35082. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor, PMID: 30355445).
  • Figure 83 illustrates chord plot showing the difference in connectivity (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m.
  • Positive and negative contrasts are rendered, respectively, in red and blue hues.
  • Positive and negative contrasts are overlayed in the same panel.
  • FC values that are very similar in both conditions are shown in gray hues.
  • thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).
  • Figure 84 illustrates chord plot for Pla+LSD vs Pla+Pla contrast for the 75 minute time point.
  • This chord plot visualizes the difference in connectivity (AFC) between the two conditions. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are shown in separate panels. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).
  • Figure 85 illustrates chord plot for Ket+LSD vs Pla+Pla contrast for the 75 minute time point.
  • This chord plot visualizes the difference in connectivity (AFC) between the two conditions. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are shown in separate panels. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).
  • Figure 86 illustrates chord plot for Pla+LSD vs Ket+LSD contrast for the 75 minute time point.
  • This chord plot visualizes the difference in connectivity (AFC) between the two conditions. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are shown in separate panels. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).
  • Figure 87 illustrates chord plot for Pla+LSD vs Pla+Pla contrast for the 300 minute time point.
  • This chord plot visualizes the difference in connectivity (AFC) between the two conditions. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are shown in separate panels. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).
  • Figure 88 illustrates chord plot for Ket+LSD vs Pla+Pla contrast for the 300 minute time point.
  • This chord plot visualizes the difference in connectivity (AFC) between the two conditions. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are shown in separate panels. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).
  • Figure 89 illustrates chord plot for Pla+LSD vs Ket+LSD contrast for the 300 minute time point.
  • This chord plot visualizes the difference in connectivity (AFC) between the two conditions. Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are shown in separate panels. FC values that are very similar in both conditions are shown in gray hues. Moreover, thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).
  • Figure 90 illustrates contrasts for Visual 1 network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m.
  • AFC Visual 1 network
  • Positive and negative contrasts are rendered, respectively, in red and blue hues.
  • Positive and negative contrasts are overlayed in the same panel.
  • FC values that are very similar in both conditions are shown in gray hues.
  • thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation.
  • Figure 91 illustrates contrasts for Visual2 network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m.
  • AFC Visual2 network
  • Positive and negative contrasts are rendered, respectively, in red and blue hues.
  • Positive and negative contrasts are overlayed in the same panel.
  • FC values that are very similar in both conditions are shown in gray hues.
  • thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation.
  • the guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).
  • Figure 92 illustrates contrasts for Somatomotor network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m.
  • AFC Somatomotor network
  • Positive and negative contrasts are rendered, respectively, in red and blue hues.
  • Positive and negative contrasts are overlayed in the same panel.
  • FC values that are very similar in both conditions are shown in gray hues.
  • thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).
  • Figure 93 illustrates contrasts for Cingulo-Opercular network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m.
  • AFC Cingulo-Opercular network
  • Positive and negative contrasts are rendered, respectively, in red and blue hues.
  • Positive and negative contrasts are overlayed in the same panel.
  • FC values that are very similar in both conditions are shown in gray hues.
  • thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).
  • Figure 94 illustrates contrasts for Dorsal-Attention network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m.
  • AFC Dorsal-Attention network
  • Positive and negative contrasts are rendered, respectively, in red and blue hues.
  • Positive and negative contrasts are overlayed in the same panel.
  • FC values that are very similar in both conditions are shown in gray hues.
  • thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).
  • Figure 95 illustrates contrasts for Language network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m.
  • AFC Language network
  • Positive and negative contrasts are rendered, respectively, in red and blue hues.
  • Positive and negative contrasts are overlayed in the same panel.
  • FC values that are very similar in both conditions are shown in gray hues.
  • thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).
  • Figure 96 illustrates contrasts for Frontoparietal network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m.
  • AFC Frontoparietal network
  • Positive and negative contrasts are rendered, respectively, in red and blue hues.
  • Positive and negative contrasts are overlayed in the same panel.
  • FC values that are very similar in both conditions are shown in gray hues.
  • thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).
  • Figure 97 illustrates contrasts for Auditory network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m.
  • AFC Auditory network
  • Positive and negative contrasts are rendered, respectively, in red and blue hues.
  • Positive and negative contrasts are overlayed in the same panel.
  • FC values that are very similar in both conditions are shown in gray hues.
  • thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).
  • Figure 98 illustrates contrasts for Default network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m.
  • AFC Default network
  • Positive and negative contrasts are rendered, respectively, in red and blue hues.
  • Positive and negative contrasts are overlayed in the same panel.
  • FC values that are very similar in both conditions are shown in gray hues.
  • thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).
  • Figure 99 illustrates contrasts for Posterior-Multimodal network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m.
  • AFC Posterior-Multimodal network
  • Positive and negative contrasts are rendered, respectively, in red and blue hues.
  • Positive and negative contrasts are overlayed in the same panel.
  • FC values that are very similar in both conditions are shown in gray hues.
  • thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation. The guide to the different regions is listed on the right (this guide reprinted from Ji et al., NeuroImage (2019)).
  • Figure 100 illustrates contrasts for Ventral-Multimodal (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m.
  • AFC Ventral-Multimodal
  • Positive and negative contrasts are rendered, respectively, in red and blue hues.
  • Positive and negative contrasts are overlayed in the same panel.
  • FC values that are very similar in both conditions are shown in gray hues.
  • thicker lines indicate stronger differences in FC between the two respective conditions. Nodes along the perimeter indicate left hemisphere cortical parcels of the CAP-NP parcellation.
  • Figure 101 illustrates contrasts for Orbito- Affective network (AFC) between the Pla+LSD Vs Pla+Pla conditions (top) Ket+LSD Vs Pla+Pla (middle) and Pla+LSD Vs Ket+LSD (Bottom) at 75min and at 300m.
  • AFC Orbito- Affective network
  • Positive and negative contrasts are rendered, respectively, in red and blue hues. Positive and negative contrasts are overlayed in the same panel. FC values that are very similar in both conditions are shown in gray hues.
  • Figure 102 illustrates AGBCz contrast maps at 75min. Left: Placebo+LSD Vs Ket+LSD AGBCz contrast map at 75 minutes. Right: The same AGBCz contrast map but thresholded such that only the bottom and top 10% of parcels are visualized. The most positive contrasts are shown in parcels of the visual network, and the most negative contrasts are shown in parcels of the cingulo-opercular network
  • Figure 103 illustrates Placebo+LSD vs Ket+LSD seed connectivity maps averaged across all parcels of the Visual (left) and Cingulo-Opercular (right) networks at 75 minutes. Seed connectivity contrasts averaged across parcels of the visual networks were strongly positive with superior temporal regions, whereas seed connectivity contrasts averaged across parcels of the cingulo-opercular network were strongly positive with visual regions and strongly negative with regions of the anterior cingulate cortex.
  • Figure 104 illustrates AGBCz contrast maps for Pla+LSD vs Ket+LSD at 300min Left: AGBCz contrast map at 300 minutes. Right: The same AGBCz contrast map but thresholded such that only the bottom and top 10% of parcels are visualized.
  • the Pla+LSD vs Ket+LSD contrast for the AGBCz metric shows strong positive contrasts in parcels of the visual network and strong negative contrasts in parcels of the cingulo-opercular network.
  • Figure 105 illustrates seed connectivity maps for Placebo+LSD vs Ket+LSD averaged across all parcels of the Visual (left) and Cingulo-Opercular networks (right) at 300 minutes. Seed connectivity contrast maps averaged across parcels of the visual networks are weak overall, whereas seed connectivity contrasts maps averaged across parcels of the cingulo-opercular network show strong positive contrasts with visual networks and superior temporal regions.
  • Figure 106 illustrates AGBCz contrast map at different timepoints for Ket+LSD vs Pla+Pla. Top: AGBCz contrast map at 75 minutes (left) 300 minutes (middle), and 300 minutes vs 75 minutes (right).
  • Figure 107 illustrates seed connectivity maps for Ket+LSD vs Pla+Pla averaged across all parcels of the Visual (left) and Cingulo-Opercular (right) networks between 75 minute and 300 minute timepoints. Seed connectivity contrasts averaged across parcels of visual networks were strongly positive with somatomotor and superior temporal regions (left). Seed connectivity contrasts averaged across parcels of the cingulo-opercular network were strongly positive with visual regions and strongly negative with somatomotor and anterior cingulate regions (right).
  • Figure 108 illustrates the pattern of changes between the 300 min and 75 min time point for Ket+LSD vs Pla+Pla contrast and the Pla+LSD vs Ket+LSD contrast at 75min for AFC (left) and for AGBCz (right).
  • the Pla+LSD vs Ket+LSD contrast, here at 75 min, is an approximation for the neural effect that Ket blocks.
  • the changes between the 75 min and 300 min time points for the Ket+LSD vs Pla+Pla contrast resemble this pattern, both at the level of AFC (left) and AGBCz (right).
  • Figure 109 illustrates alignment of gene expression maps with contrast maps.
  • the Pearson correlation of the 5HT2A gene expression map with the contrast maps is highlighted in blue.
  • the alignment of the 5HT2A expression map is opposite for the Ket+LSD vs Pla+Pla condition at the 75 min time point compared to the other shown conditions and time points.
  • FIG. 110 depicts the XRPD pattern of ketanserin L-tartrate Pattern A.
  • FIG. Ill depicts the XRPD pattern of ketanserin L-malate Pattern A.
  • FIG. 112 depicts the XRPD pattern of ketanserin succinate Pattern A.
  • FIG. 113 depicts the XRPD pattern of ketanserin succinate Pattern A.
  • FIG. 114 depicts the XRPD pattern of ketanserin L-tartrate Group 3.
  • FIG. 115 depicts the XRPD pattern of ketanserin succinate Pattern C.
  • FIG. 116 depicts the XRPD pattern of ketanserin free base form Pattern A.
  • FIG. 117 depicts the ’H-NMR of ketanserin besylate Pattern A.
  • FIG. 118 depicts the ’H-NMR of ketanserin besylate Pattern B.
  • FIG. 119 depicts the X H-NMR of ketanserin citrate Pattern A.
  • FIG. 120 depicts the DSC curve of ketanserin citrate Pattern A.
  • FIG. 121 depicts the ’H-NMR of ketanserin esylate Pattern A.
  • FIG. 122 depicts the ’H-NMR of ketanserin esylate Pattern B.
  • FIG. 123 depicts the ’H-NMR of ketanserin esylate Pattern C.
  • FIG. 124 depicts the ’H-NMR of ketanserin fumarate Pattern A.
  • FIG. 125 depicts the DSC curve of ketanserin fumarate Pattern A.
  • FIG. 126 depicts the ’H-NMR of ketanserin fumarate Pattern B.
  • FIG. 127 depicts the DSC curve of ketanserin fumarate Pattern B.
  • FIG. 128 depicts the X H-NMR of ketanserin hydrochloride Pattern A.
  • FIG. 129 depicts the DSC curve of ketanserin hydrochloride Pattern A.
  • FIG. 130 depicts the TGA curve of ketanserin hydrochloride Pattern A.
  • FIG. 131 depicts the ’H-NMR of ketanserin maleate Pattern A.
  • FIG. 132 depicts the DSC curve of ketanserin maleate Pattern A.
  • FIG. 133 depicts the TGA curve of ketanserin maleate Pattern A.
  • FIG. 134 depicts the ’H-NMR of ketanserin mesylate Pattern A.
  • FIG. 135 depicts the ’H-NMR of ketanserin mesylate Pattern B.
  • FIG. 136 depicts the ’H-NMR of ketanserin sulfate Pattern A.
  • FIG. 137 depicts the DSC curve of ketanserin sulfate Pattern A.
  • FIG. 138 depicts the TGA curve of ketanserin sulfate Pattern A.
  • FIG. 139 depicts the ’H-NMR of ketanserin p-tosylate Pattern A.
  • FIG. 140 depicts the DSC curve of ketanserin p-tosylate Pattern A.
  • FIG. 141 depicts the X H-NMR of ketanserin free base form Pattern A.
  • FIG. 142 depicts the DSC curve of ketanserin free base form Pattern A.
  • FIG. 143 depicts the TGA curve of ketanserin free base form Pattern A.
  • FIG. 144 depicts the X H-NMR of ketanserin free base form Pattern B.
  • FIG. 145 depicts the DSC curve of ketanserin free base form Pattern B.
  • FIG. 146 depicts the TGA curve of ketanserin free base form Pattern B.
  • FIG. 147 depicts the 'H-NMR of ketanserin free base form Pattern C.
  • FIG. 148 depicts the DSC curve of ketanserin free base form Pattern C.
  • FIG. 149 depicts the TGA curve of ketanserin free base form Pattern C.
  • FIG. 150 depicts the 'H-NMR of ketanserin free base form Pattern D.
  • FIG. 151 depicts the DSC curve of ketanserin free base form Pattern D.
  • FIG. 152 depicts the TGA curve of ketanserin free base form Pattern D.
  • FIG. 153 depicts the IR spectrum of ketanserin free base form Pattern A.
  • FIG. 154 depicts the IR spectrum of ketanserin L-tartrate Pattern A.
  • FIG. 155 depicts the IR spectrum of ketanserin L-malate Pattern A.
  • FIG. 156 depicts the IR spectrum of ketanserin succinate Pattern A.
  • FIG. 157 depicts the DVS pattern of ketanserin free base form Pattern A.
  • FIG. 158 depicts the DVS pattern of ketanserin L-tartrate Pattern A.
  • FIG. 159 depicts the DVS pattern of ketanserin L-malate Pattern A.
  • FIG. 160 depicts the DVS pattern of ketanserin succinate Pattern A.
  • FIG. 161 depicts the XRPD overlay of a variable temperature (VT) XRPD experiment using succinate Pattern F as starting material.
  • VT variable temperature
  • FIG. 162 depicts the XRPD overlay of a variable temperature (VT) XRPD experiment using L- T artrate pattern A as starting material. Pattern F.
  • VT variable temperature
  • FIG. 163 XRPD overlay of samples obtained from ketanserin L-tartrate Variable Humidity XRPD (VH-XRPD) experiments.
  • FIG. 164 XRPD overlay of samples obtained from ketanserin L-tartrate VH-XRPD experiments.
  • FIG. 165 XRPD overlay of samples obtained from ketanserin L-tartrate VH-XRPD experiments.
  • FIG. 166 depicts the 'H-NMR of ketanserin L-malate Pattern A.
  • FIG. 167 depicts the DSC curve of ketanserin L-malate Pattern A.
  • FIG. 168 depicts the TGA curve of ketanserin L-malate Pattern A.
  • FIG. 169 depicts the TGA curve of ketanserin L-malate Pattern B.
  • FIG. 170 depicts the 'H-NMR of ketanserin L-malate Pattern C*.
  • FIG. 171 depicts the 'H-NMR of ketanserin L-malate Pattern D.
  • FIG. 172 depicts the DSC curve of ketanserin L-malate Pattern D.
  • FIG. 173 depicts the TGA curve of ketanserin L-malate Pattern D.
  • FIG. 174 depicts the 'H-NMR of ketanserin L-malate Pattern E.
  • FIG. 175 depicts the DSC curve of ketanserin L-malate Pattern E.
  • FIG. 176 depicts the TGA curve of ketanserin L-malate Pattern E.
  • FIG. 177 depicts the 'H-NMR of ketanserin succinate Pattern A.
  • FIG. 178 depicts the DSC curve of ketanserin succinate Pattern A.
  • FIG. 179 depicts the TGA curve of ketanserin succinate Pattern A.
  • FIG. 180 depicts the 'H-NMR of ketanserin succinate Pattern B.
  • FIG. 181 depicts the DSC curve of ketanserin succinate Pattern B.
  • FIG. 182 depicts the TGA curve of ketanserin succinate Pattern B.
  • FIG. 183 depicts the 'H-NMR of ketanserin succinate Pattern C.
  • FIG. 184 depicts the DSC curve of ketanserin succinate Pattern C.
  • FIG. 185 depicts the TGA curve of ketanserin succinate Pattern C.
  • FIG. 186 depicts the 'H-NMR of ketanserin succinate Pattern D.
  • FIG. 187 depicts the DSC curve of ketanserin succinate Pattern D.
  • FIG. 188 depicts the TGA curve of ketanserin succinate Pattern D.
  • FIG. 189 depicts the 'H-NMR of ketanserin succinate Pattern E.
  • FIG. 190 depicts the DSC curve of ketanserin succinate Pattern E.
  • FIG. 191 depicts the TGA curve of ketanserin succinate Pattern E.
  • FIG. 192 depicts the 'H-NMR of ketanserin succinate Pattern F.
  • FIG. 193 depicts the DSC curve of ketanserin succinate Pattern F.
  • FIG. 194 depicts the TGA curve of ketanserin succinate Pattern F.
  • FIG. 195 depicts the 'H-NMR of ketanserin succinate Pattern G.
  • FIG. 196 depicts the 'H-NMR of ketanserin succinate Pattern H.
  • FIG. 197 depicts the DSC curve of ketanserin succinate Pattern H.
  • FIG. 198 depicts the TGA curve of ketanserin succinate Pattern H.
  • FIG. 199 depicts the 'H-NMR of ketanserin L-tartrate Pattern A.
  • FIG. 200 depicts the DSC curve of ketanserin L-tartrate Pattern A.
  • FIG. 201 depicts the TGA curve of ketanserin L-tartrate Pattern A.
  • FIG. 202 depicts the 'H-NMR of ketanserin L-tartrate Pattern B.
  • FIG. 203 depicts the DSC curve of ketanserin L-tartrate Pattern B.
  • FIG. 204 depicts the TGA curve of ketanserin L-tartrate Pattern B.
  • FIG. 205 depicts the 'H-NMR of ketanserin L-tartrate Pattern C.
  • FIG. 206 depicts the DSC curve of ketanserin L-tartrate Pattern C.
  • FIG. 207 depicts the TGA curve of ketanserin L-tartrate Pattern C.
  • FIG. 208 depicts the 'H-NMR of ketanserin L-tartrate Pattern D.
  • FIG. 209 depicts the 'H-NMR of ketanserin L-tartrate Pattern E.
  • FIG. 210 depicts the 'H-NMR of ketanserin L-tartrate Pattern F.
  • FIG. 211 depicts the 'H-NMR of ketanserin L-tartrate Pattern G.
  • FIG. 212 depicts the 'H-NMR of ketanserin L-tartrate Pattern H.
  • FIG. 213 depicts the DSC curve of ketanserin L-tartrate Pattern H.
  • FIG. 214 depicts the TGA curve of ketanserin L-tartrate Pattern H.
  • FIG. 215 depicts the 'H-NMR of ketanserin L-tartrate Pattern I.
  • FIG. 216 depicts the DSC curve of ketanserin L-tartrate Pattern I.
  • FIG. 217 depicts the TGA curve of ketanserin L-tartrate Pattern I.
  • FIG. 218 depicts the 'H-NMR of ketanserin L-tartrate Pattern J.
  • FIG. 219 depicts the DSC curve of ketanserin L-tartrate Pattern J.
  • FIG. 220 depicts the TGA curve of ketanserin L-tartrate Pattern J.
  • FIG. 221 depicts the 'H-NMR of ketanserin L-tartrate Pattern K.
  • FIG. 222 depicts the DSC curve of ketanserin L-tartrate Pattern K.
  • FIG. 223 depicts the TGA curve of ketanserin L-tartrate Pattern K.
  • FIG. 224 depicts the 'H-NMR of ketanserin L-tartrate Pattern L.
  • FIG. 225 depicts the DSC curve of ketanserin L-tartrate Pattern L.
  • FIG. 226 depicts the TGA curve of ketanserin L-tartrate Pattern L.
  • FIG. 227 depicts the 'H-NMR of ketanserin L-tartrate Pattern M.
  • FIG. 228 depicts the DSC curve of ketanserin L-tartrate Pattern M.
  • FIG. 229 depicts the TGA curve of ketanserin L-tartrate Pattern M.
  • FIG. 230 depicts the 'H-NMR of ketanserin L-tartrate Pattern N.
  • FIG. 231 depicts the DSC curve of ketanserin L-tartrate Pattern N.
  • FIG. 232 depicts the TGA curve of ketanserin L-tartrate Pattern N.
  • FIG. 233 depicts the 'H-NMR of ketanserin L-tartrate Pattern O.
  • FIG. 234 depicts the DSC curve of ketanserin L-tartrate Pattern O.
  • FIG. 235 depicts the TGA curve of ketanserin L-tartrate Pattern O.
  • FIG. 236 depicts the 'H-NMR of ketanserin L-tartrate Pattern P.
  • FIG. 237 depicts the 'H-NMR of ketanserin L-tartrate Pattern Q.
  • FIG. 238 depicts the DSC curve of ketanserin L-tartrate Pattern Q.
  • FIG. 239 depicts the TGA curve of ketanserin L-tartrate Pattern Q.
  • FIG. 240 depicts the 'H-NMR of ketanserin L-tartrate Pattern R.
  • FIG. 241 depicts the DSC curve of ketanserin L-tartrate Pattern R.
  • FIG. 242 depicts the TGA curve of ketanserin L-tartrate Pattern R.
  • FIG. 243 depicts the 'H-NMR of ketanserin L-tartrate Pattern S.
  • FIG. 244 depicts the DSC curve of ketanserin L-tartrate Pattern S.
  • FIG. 245 depicts the TGA curve of ketanserin L-tartrate Pattern S.
  • FIG. 246 depicts the 'H-NMR of ketanserin L-tartrate Group 1.
  • FIG. 247 depicts the DSC curve of ketanserin L-tartrate Group 1.
  • FIG. 248 depicts the TGA curve of ketanserin L-tartrate Group 1.
  • FIG. 249 depicts the 'H-NMR of ketanserin L-tartrate Group 2.
  • FIG. 250 depicts the DSC curve of ketanserin L-tartrate Group 2.
  • FIG. 251 depicts the TGA curve of ketanserin L-tartrate Group 2.
  • FIG. 252 depicts the 'H-NMR of ketanserin L-tartrate Group 3.
  • FIG. 253 depicts the DSC curve of ketanserin L-tartrate Group 3.
  • FIG. 254 depicts the TGA curve of ketanserin L-tartrate Group 3.
  • FIG. 255 depicts the 'H-NMR of ketanserin L-tartrate Group 4.
  • FIG. 256 depicts the DSC curve of ketanserin L-tartrate Group 4.
  • FIG. 257 depicts the TGA curve of ketanserin L-tartrate Group 4.
  • FIG. 258 depicts the 'H-NMR of ketanserin L-tartrate Group 5.
  • FIG. 259 depicts the DSC curve of ketanserin L-tartrate Group 5.
  • FIG. 260 depicts the TGA curve of ketanserin L-tartrate Group 5.
  • FIG. 261 depicts the XRPD pattern of ketanserin maleate Pattern B.
  • FIG. 262 depicts the XRPD pattern of ketanserin sulfate Pattern B.
  • FIG. 263 depicts the 'H-NMR of ketanserin sulfate Pattern B.
  • FIG. 264 depicts the DSC curve of ketanserin sulfate Pattern B.
  • FIG. 265 depicts the TGA curve of ketanserin sulfate Pattern B.
  • FIG. 266 depicts the X H-NMR of ketanserin L-malate Pattern B.
  • FIG. 267 depicts the DSC curve of ketanserin L-malate Pattern B.
  • novel solid forms and salts of ketanserin that have superior properties to known forms. Accordingly, disclosed herein are novel forms of ketanserin, including solid forms of ketanserin free form, salts of ketanserin and solid forms thereof, including crystalline forms of the compound and salts thereof, as well as polymorphs of the solid forms.
  • the solid form of ketanserin is a form of the free base form of the compound, such as polymorph of the free base form of the compound.
  • the solid form of ketanserin is a salt, and may be a polymorph of the salt.
  • the salt may be formed from an acid selected from hydrochloric acid, fumaric acid, galactaric (mucic) acid, naphthalene- 1,5-disulfonic acid, citric acid, sulfuric acid, ⁇ /-glucuronic acid, ethane- 1,2-disulfonic acid, lactobionic acid,/?-toluenesulfonic acid, D-glucoheptonic acid, thiocyanic acid, (-)-Z-pyroglutamic acid, methanesulfonic acid, /.-malic acid, dodecylsulfuric acid, hippuric acid, naphthalene-2-sulfonic acid, //-gluconic acid, benzenesulfonic acid, D,L- lactic acid, oxalic acid, oleic acid, glycerophosphoric acid, succinic acid, ethanesulfonic acid 2- hydroxy, glutaric acid, Z-aspartic acid,
  • the solid form may be a crystalline solid, a hydrate, or a combination thereof.
  • the crystalline solid may be substantially a single form, such as a polymorph form.
  • the polymorph may be selected to have one or more desired properties, particularly improved properties, such as physical properties, chemical properties, pharmacokinetic properties, or a combination thereof.
  • the one or more desired properties may comprise melting point, glass transition temperature, flowability, thermal stability, mechanical stability, shelf life, stability against polymorphic transition, hygroscopic properties, solubility in water and/or organic solvents, reactivity, compatibility with excipients and/or delivery vehicles, bioavailability, absorption, distribution, metabolism, excretion, toxicity including cytotoxicity, dissolution rate, half-life, or a combination thereof.
  • a pharmaceutical composition comprising a salt and/or a solid form of ketanserin, and a pharmaceutically acceptable excipient.
  • a method for administering salts and solid forms of ketanserin also is disclosed herein.
  • the method comprises administering to a subject an effective amount of a solid form of ketanserin, or a pharmaceutical composition thereof.
  • the subject is suffering from a neurological disease or a psychiatric disorder, or both, such as a neurodegenerative disorder.
  • the neurological disorder or psychiatric disorder, or both may comprise depression, addiction, anxiety, or a post-traumatic stress disorder, and/or the neurological disorder or psychiatric disorder, or both, may comprise treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, or substance use disorder.
  • the neurological disorder or psychiatric disorder, or both comprises stroke, traumatic brain injury, or a combination thereof.
  • the method may comprise further comprising administering an effective amount of an psychedelic agent to the subject.
  • administering the solid form of the compound comprises oral, parenteral, or topical administration.
  • oral administration is used, but in other particular embodiments, administration is by injection, inhalation, intraocular, intravaginal, intrarectal or transdermal routes.
  • administering refers to any suitable mode of administration, including, oral administration, administration as a suppository, topical contact, parenteral, intravenous, intraperitoneal, intramuscular, intralesional, intranasal or subcutaneous administration, intrathecal administration, or the implantation of a slow-release device e.g., a mini-osmotic pump, to the subject.
  • a slow-release device e.g., a mini-osmotic pump
  • Ketanserin refers to the compound: which is marketed under the trade name “Sufrexal” and has CAS number 74050-98-9.
  • Subject refers to an animal, such as a mammal, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In certain embodiments, the subject is a human subject.
  • “Therapeutically effective amount” or “therapeutically sufficient amount” or “effective or sufficient amount” refers to a dose that produces therapeutic effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins). In sensitized cells, the therapeutically effective dose can often be lower than the conventional therapeutically effective dose for non-sensitized cells.
  • Neuronal plasticity refers to the ability of the brain to change its structure and/or function continuously throughout a subject’s life. Examples of the changes to the brain include, but are not limited to, the ability to adapt or respond to internal and/or external stimuli, such as due to an injury, and the ability to produce new neurites, dendritic spines, and synapses.
  • Brain disorder refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post- traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.
  • Combination therapy refers to a method of treating a disease or disorder, wherein two or more different pharmaceutical agents are administered in overlapping regimens so that the subject is simultaneously exposed to both agents.
  • the compounds of the invention can be used in combination with other pharmaceutically active compounds.
  • the compounds of the invention can be administered simultaneously (as a single preparation or separate preparation) or sequentially to the other drug therapy.
  • a combination therapy envisions administration of two or more drugs during a single cycle or course of therapy.
  • modified release relates to formulations that have a different release profile than a standard formulation.
  • modified release coating encompasses coatings that delay release, sustain release, extend release, prevent release, minimize release and/or otherwise prolong the release of a drug relative to formulations lacking such coatings which release a drug relatively quickly (i.e., “immediate release” compositions).
  • modified release encompasses “sustained release,” “extended release,” “delayed release,” including “delayed immediate release” and the like.
  • modified release is used in an overlapping fashion with “controlled release” or “delayed release”.
  • modified-release or “delayed release” dosage composition refers broadly to a dosage form showing one or more modified-release properties, as described herein.
  • Neurotrophic factors refers to a family of soluble peptides or proteins which support the survival, growth, and differentiation of developing and mature neurons.
  • Modulate or “modulating” or “modulation” refers to an increase or decrease in the amount, quality, or effect of a particular activity, function or molecule.
  • agonists, partial agonists, antagonists, and allosteric modulators e.g., a positive allosteric modulator
  • a G protein-coupled receptor e.g., 5HT2A
  • Agonism refers to the activation of a receptor or enzyme by a modulator, or agonist, to produce a biological response.
  • “Agonist” refers to a modulator that binds to a receptor or enzyme and activates the receptor to produce a biological response.
  • “5HT2A agonist” can be used to refer to a compound that exhibits an ECso with respect to 5HT2A activity of no more than about 100 mM.
  • the term “agonist” includes full agonists or partial agonists.
  • “Full agonist” refers to a modulator that binds to and activates a receptor with the maximum response that an agonist can elicit at the receptor.
  • “Partial agonist” refers to a modulator that binds to and activates a given receptor, but has partial efficacy, that is, less than the maximal response, at the receptor relative to a full agonist.
  • “Positive allosteric modulator” refers to a modulator that binds to a site distinct from the orthosteric binding site and enhances or amplifies the effect of an agonist.
  • Antagonist refers to the inactivation of a receptor or enzyme by a modulator, or antagonist. Antagonism of a receptor, for example, is when a molecule binds to the receptor and does not allow activity to occur.
  • Antagonist or “neutral antagonist” refers to a modulator that binds to a receptor or enzyme and blocks a biological response. An antagonist has no activity in the absence of an agonist or inverse agonist but can block the activity of either, causing no change in the biological response.
  • composition refers to a product comprising the specified ingredients in the specified amounts, as well as any product, which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.
  • pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation.
  • “Pharmaceutically acceptable excipient” refers to a substance that aids the administration of an active agent to and absorption by a subject.
  • Pharmaceutical excipients useful in the present invention include, but are not limited to, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors and colors.
  • binders include, but are not limited to, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors and colors.
  • salts and solid forms of ketanserin that are useful to treat various disorders, such as brain disorders. Also disclosed are methods for making the salts and solid forms of ketanserin and method of administering the salts and solid forms of the compound
  • a solid form of the compound is a crystalline form of ketanserin.
  • the solid form of ketanserin is a polymorph of ketanserin, such as a polymorph of the free base compound or a polymorph of the salt.
  • the solid form of the compound is a salt of the compound.
  • the solid form of the compound is a crystalline salt form of the compound, such as an acid addition salt form.
  • the solid form of ketanserin comprises a salt of ketanserin.
  • Suitable salts include pharmaceutically acceptable salts of ketanserin.
  • the solid form of ketanserin is not, and does not include, ketanserin tartrate.
  • the salt of ketanserin may be formed from a suitable pharmaceutically acceptable acid, including, without limitation, inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, as well as organic acids such as formic acid, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, benzene sulfonic acid, isethionic acid, methanesulfonic acid, ethanesulfonic acid, -toluenesulfonic acid, salicylic acid, xinafoic acid and the like. Additional information concerning pharmaceutically acceptable salts can be found in, for example, S. M. Berge, et al., “Pharmaceutical Salts,”
  • the salt may be formed using an acid from Table 1. Table 1
  • hydrochloric acid is not used.
  • the acid salts of ketanserin disclosed herein can have any suitable stoichiometric ratio of acid to ketanserin.
  • the molar ratio of acid to ketanserin is from about 0.4 to about 2.2, such as forms wherein the salt has a stoichiometric ratio of acid to ketanserin of from about 0.5 to about 2, such as about 0.5, about 1 or about 2.
  • Embodiments of ketanserin of the present disclosure are in a solid form.
  • the solid form may be a crystalline form or an amorphous form.
  • the solid form is a crystalline form, such as a polymorph.
  • the solid form of ketanserin is a free base form of ketanserin.
  • the solid form of ketanserin is a salt.
  • the solid form is a crystalline salt form of the compound.
  • solid forms of ketanserin such as crystalline forms including salt and non-salt crystalline forms of ketanserin, may exist in more than one crystal form. Such different forms are referred to as polymorphs.
  • the disclosed compounds are particular polymorphs of ketanserin or a ketanserin salt.
  • the solid form of ketanserin disclosed herein is selected to be a crystalline form, such as a particular polymorph of a crystalline form of ketanserin that provides one or more desired properties.
  • the crystalline form offers advantages over the amorphous form of the molecule.
  • the disclosed polymorph offers improved properties as compared to another polymorph of ketanserin.
  • the ketanserin may be a salt or free base compound.
  • the one or more desired properties may include, but are not limited to, physical properties, including but not limited to, melting point, glass transition temperature, flowability, and/or stability, such as thermal stability, mechanical stability, shelf life, stability against polymorphic transition, etc.; chemical properties, such as, but not limited to, hygroscopic properties, solubility in water and/or organic solvents, reactivity, compatibility with excipients and/or delivery vehicles; and/or pharmacokinetic properties, such as, but not limited to, bioavailability, absorption, distribution, metabolism, excretion, toxicity including cytotoxicity, dissolution rate, and/or half-life.
  • physical properties including but not limited to, melting point, glass transition temperature, flowability, and/or stability, such as thermal stability, mechanical stability, shelf life, stability against polymorphic transition, etc.
  • chemical properties such as, but not limited to, hygroscopic properties, solubility in water and/or organic solvents, reactivity, compatibility with excipients and/or delivery vehicles
  • the desired polymorph may be produced by techniques known to persons of ordinary skill in the art. Such techniques include, but are not limited to, crystallization in particular solvents and/or at particular temperatures, supersaturation, using a precipitation agent, such as a salt, glycol, alcohol, etc., co-crystallization, lyophilization, spray drying, freeze drying, and/or complexing with an inert agent.
  • a precipitation agent such as a salt, glycol, alcohol, etc.
  • co-crystallization such as a salt, glycol, alcohol, etc.
  • lyophilization such as a salt, glycol, alcohol, etc.
  • spray drying such as g., freeze drying, and/or complexing with an inert agent.
  • ketanserin Techniques to identify a particular solid form of ketanserin are known to persons of ordinary skill in the art, and include, but are not limited to, X-ray crystallography, X-ray diffraction, electron crystallography, powder diffraction, including X-ray, neutron, or electron diffraction, X-ray fiber diffraction, small-angle X-ray scattering, and/or melting point.
  • the present disclosure provides solid forms of free base form Pattern A, e.g., crystalline forms of free base form Pattern A.
  • the free base form Pattern A XRPD profile is substantially similar to that shown in any one of FIGs. 1, 44, 63, or 116.
  • the free base form Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 141.
  • the free base form Pattern A TGA profile is substantially similar to that shown in FIG. 143.
  • the free base form Pattern A DSC profile is substantially similar to that shown in FIG. 142.
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by an XRPD signal at 9.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation). In some embodiments, the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °29 and 21.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 9.5 °20, 21.0 °20, and 14.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °29, 21.0 °29, and 14.2 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °20, 21.0 °20, 14.2 °20, and 4.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °29, 21.0 °29, 14.2 °29, and 4.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, and 20.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °29, 21.0 °29, 14.2 °20, 4.7 °20, and 20.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, and 27.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °29, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, and 27.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, 27.6 °20, and 26.8 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °29, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, 27.6 °20, and 26.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, 27.6 °20, 26.8 °20, and 17.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, 27.6 °20, 26.8 °20, and 17.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, 27.6 °20, 26.8 °20, 17.5 °20, and 18.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, 27.6 °20, 26.8 °20, 17.5 °20, and 18.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, 27.6 °20, 26.8 °20, 17.5 °20, 18.8 °20, and 10.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.5 °20, 21.0 °20, 14.2 °20, 4.7 °20, 20.1 °20, 27.6 °20, 26.8 °20, 17.5 °20, 18.8 °20, and 10.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • Table 2 is a numerical representation of selected XRPD signals shown in at least Figure 1.
  • the crystalline free base form Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen XRPD signals selected from those set forth in Table 2.
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by an XRPD signal at 21.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °29 and 20.2 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.0 °20, 20.2 °20, and 27.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °29, 20.2 °29, and 27.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 20.2 °20, 27.7 °20, and 18.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °29, 20.2 °29, 27.7 °29, and 18.9 °29 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, and 17.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °29, 20.2 °29, 27.7 °29, 18.9 °20, and 17.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, and 26.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °29, 20.2 °29, 27.7 °20, 18.9 °20, 17.5 °20, and 26.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, and 10.7 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °29, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, and 10.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, 10.7 °20, and 19.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, 10.7 °20, and 19.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, 10.7 °20, 19.7 °20, and 16.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, 10.7 °20, 19.7 °20, and 16.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, 10.7 °20, 19.7 °20, 16.4 °29, and 9.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 21.0 °20, 20.2 °20, 27.7 °20, 18.9 °20, 17.5 °20, 26.9 °20, 10.7 °20, 19.7 °20, 16.4 °20, and 9.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • Table 3 is a numerical representation of selected XRPD signals shown in at least Figure 63.
  • the crystalline free base form Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, or ten XRPD signals selected from those set forth in Table 3.
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by an XRPD signal at 9.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °29 and 20.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 9.4 °29, 20.9 °29, and 14.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °29, 20.9 °29, and 14.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 20.9 °29, 14.1 °29, and 4.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °29, 20.9 °29, 14.1 °29, and 4.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 20.9 °29, 14.1 °29, 4.7 °29, and 20.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °29, 20.9 °29, 14.1 °29, 4.7 °29, and 20.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °29, 20.9 °29, 14.1 °29, 4.7 °29, 20.1 °29, and 17.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °29, 20.9 °29, 14.1 °20, 4.7 °20, 20.1 °20, and 17.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °20, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, and 19.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °29, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, and 19.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °20, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, 19.7 °20, and 27.6 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °20, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, 19.7 °20, and 27.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °20, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, 19.7 °20, 27.6 °20, and 18.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °20, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, 19.7 °20, 27.6 °20, and 18.8 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.4 °20, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, 19.7 °20, 27.6 °20, 18.8 °29, and 10.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of free base form Pattern A is crystalline free base form Pattern A characterized by XRPD signals at 9.4 °20, 20.9 °20, 14.1 °20, 4.7 °20, 20.1 °20, 17.5 °20, 19.7 °20, 27.6 °20, 18.8 °20, and 10.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • Table 4 is a numerical representation of selected XRPD signals shown in at least Figure 44.
  • the crystalline free base form Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen XRPD signals selected from those set forth in Table 4.
  • Solid forms of free base form Pattern B In some embodiments, the present disclosure provides solid forms of free base form
  • Pattern B e.g., crystalline forms of free base form Pattern B.
  • the free base form Pattern B XRPD profile is substantially similar to that shown in FIGs. 2 or 45.
  • the free base form Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 144.
  • the free base form Pattern B TGA profile is substantially similar to that shown in FIG. 146.
  • the free base form Pattern B DSC profile is substantially similar to that shown in FIG. 145.
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by an XRPD signal at 16.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °29 and 26.2 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 16.8 °20, 26.2 °20, and 27.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °29, 26.2 °29, and 27.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °20, 26.2 °20, 27.0 °20, and 16.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °29, 26.2 °29, 27.0 °20, and 16.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, and 14.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °29, 26.2 °29, 27.0 °20, 16.2 °20, and 14.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, and 22.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °29, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, and 22.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, and 21.7 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °29, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, and 21.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, 21.7 °20, and 22.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, 21.7 °20, and 22.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, 21.7 °20, 22.3 °20, and 13.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, 21.7 °20, 22.3 °20, and 13.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, 21.7 °20, 22.3 °20, 13.5 °20, and 13.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern B is crystalline free base form Pattern B characterized by XRPD signals at 16.8 °20, 26.2 °20, 27.0 °20, 16.2 °20, 14.8 °20, 22.2 °20, 21.7 °20, 22.3 °20, 13.5 °20, and 13.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • Table 5 is a numerical representation of selected XRPD signals shown in at least Figure 2.
  • the crystalline free base form Pattern B is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, or eighteen XRPD signals selected from those set forth in Table 5.
  • the present disclosure provides solid forms of free base form Pattern C, e.g., crystalline forms of free base form Pattern C.
  • the free base form Pattern C XRPD profile is substantially similar to that shown in FIG. 46.
  • the free base form Pattern C 1H NMR spectrum is substantially similar to that shown in FIG. 147.
  • the free base form Pattern C TGA profile is substantially similar to that shown in FIG. 149.
  • the free base form Pattern C DSC profile is substantially similar to that shown in FIG. 148.
  • the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by an XRPD signal at 14.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by XRPD signals at 14.9 °29 and 22.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by two or more, or three XRPD signals selected from the group consisting of 14.9 °20, 22.3 °20, and 7.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by XRPD signals at 14.9 °29, 22.3 °29, and 7.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °20, 22.3 °20, 7.4 °20, and 9.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by XRPD signals at 14.9 °29, 22.3 °29, 7.4 °29, and 9.5 °29 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °20, 22.3 °20, 7.4 °20, 9.5 °20, and 11.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by XRPD signals at 14.9 °29, 22.3 °29, 7.4 °29, 9.5 °20, and 11.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °20, 22.3 °20, 7.4 °20, 9.5 °20, 11.1 °20, and 3.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by XRPD signals at 14.9 °29, 22.3 °29, 7.4 °20, 9.5 °20, 11.1 °20, and 3.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °20, 22.3 °20, 7.4 °20, 9.5 °20, 11.1 °20, 3.7 °20, and 14.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by XRPD signals at 14.9 °29, 22.3 °20, 7.4 °20, 9.5 °20, 11.1 °20, 3.7 °20, and 14.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °20, 22.3 °20, 7.4 °20, 9.5 °20, 11.1 °20, 3.7 °20, 14.2 °20, and 18.6 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by XRPD signals at 14.9 °20, 22.3 °20, 7.4 °20, 9.5 °20, 11.1 °20, 3.7 °20, 14.2 °20, and 18.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °20, 22.3 °20, 7.4 °20, 9.5 °20, 11.1 °20, 3.7 °20, 14.2 °20, 18.6 °20, and 21.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of free base form Pattern C is crystalline free base form Pattern C characterized by XRPD signals at 14.9 °20, 22.3 °20, 7.4 °20, 9.5 °20, 11.1 °20, 3.7 °20, 14.2 °20, 18.6 °20, and 21.0 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • Table 6 is a numerical representation of selected XRPD signals shown in at least Figure 46.
  • the crystalline free base form Pattern C is characterized by one, two, three, four, five, six, seven, eight, or nine XRPD signals selected from those set forth in Table 6.
  • the present disclosure provides solid forms of free base form Pattern D, e.g., crystalline forms of free base form Pattern D.
  • the free base form Pattern D XRPD profile is substantially similar to that shown in FIG. 64.
  • the free base form Pattern D 1H NMR spectrum is substantially similar to that shown in FIG. 150.
  • the free base form Pattern D TGA profile is substantially similar to that shown in FIG. 152.
  • the free base form Pattern D DSC profile is substantially similar to that shown in FIG. 151.
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by an XRPD signal at 8.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °29 and 16.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by two or more, or three XRPD signals selected from the group consisting of 8.8 °20, 16.1 °20, and 17.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °29, 16.1 °29, and 17.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °20, 16.1 °20, 17.5 °20, and 18.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °29, 16.1 °29, 17.5 °29, and 18.9 °29 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, and 10.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °29, 16.1 °29, 17.5 °29, 18.9 °20, and 10.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, and 24.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °29, 16.1 °29, 17.5 °20, 18.9 °20, 10.4 °20, and 24.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, and 17.1 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °29, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, and 17.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, 17.1 °20, and 3.5 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, 17.1 °20, and 3.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, 17.1 °20, 3.5 °20, and 4.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, 17.1 °20, 3.5 °20, and 4.0 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, 17.1 °20, 3.5 °20, 4.0 °29, and 21.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of free base form Pattern D is crystalline free base form Pattern D characterized by XRPD signals at 8.8 °20, 16.1 °20, 17.5 °20, 18.9 °20, 10.4 °20, 24.3 °20, 17.1 °20, 3.5 °20, 4.0 °20, and 21.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • Table 7 is a numerical representation of selected XRPD signals shown in at least Figure 64.
  • the crystalline free base form Pattern D is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, or eighteen XRPD signals selected from those set forth in Table 7.
  • the present disclosure provides solid forms of ketanserin hydrochloride Pattern A, e.g., crystalline forms of ketanserin hydrochloride Pattern A.
  • the ketanserin hydrochloride Pattern A XRPD profile is substantially similar to that shown in FIG. 3.
  • the ketanserin hydrochloride Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 128.
  • the ketanserin hydrochloride Pattern A TGA profile is substantially similar to that shown in FIG. 130.
  • the ketanserin hydrochloride Pattern A DSC profile is substantially similar to that shown in FIG. 129.
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by an XRPD signal at 15.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °29 and 18.3 °29 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 15.5 °29, 18.3 °29, and 24.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °29, 18.3 °20, and 24.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °29, 18.3 °29, 24.6 °29, and 10.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °20, 18.3 °20, 24.6 °20, and 10.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °29, 18.3 °29, 24.6 °29, 10.7 °29, and 25.2 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °20, and 25.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °29, 18.3 °29, 24.6 °29, 10.7 °29, 25.2 °29, and 22.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °20, 25.2 °20, and 22.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °20, 25.2 °20, 22.9 °20, and 14.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °20, 25.2 °20, 22.9 °20, and 14.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °20, 25.2 °20, 22.9 °20,
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °20, 25.2 °20, 22.9 °20, 14.1 °20, and 5.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °20, 25.2 °20, 22.9 °20,
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °29, 18.3 °29, 24.6 °29, 10.7 °29,
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.5 °20, 18.3 °20, 24.6 °20, 10.7 °20, 25.2 °20, 22.9 °20,
  • the solid form of ketanserin hydrochloride Pattern A is crystalline ketanserin hydrochloride Pattern A characterized by XRPD signals at 15.5 °29, 18.3 °29, 24.6 °29, 10.7 °29,
  • Table 8 is a numerical representation of selected XRPD signals shown in at least Figure 3.
  • the crystalline ketanserin hydrochloride Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty XRPD signals selected from those set forth in Table 8.
  • Solid forms of ketanserin hydrochloride Pattern B In some embodiments, the present disclosure provides solid forms of ketanserin hydrochloride Pattern B, e.g., crystalline forms of ketanserin hydrochloride Pattern B. In some embodiments, the ketanserin hydrochloride Pattern B XRPD profile is substantially similar to that shown in FIG. 17.
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by an XRPD signal at 25.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °29 and 14.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 25.6 °29, 14.8 °29, and 26.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °29, 14.8 °29, and 26.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.6 °29, 14.8 °29, 26.8 °29, and 7.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °29, 14.8 °29, 26.8 °29, and 7.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.6 °29, 14.8 °29, 26.8 °29, 7.3 °29, and 13.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °29, 14.8 °29, 26.8 °29, 7.3 °29, and 13.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.6 °29, 14.8 °29, 26.8 °29, 7.3 °29, 13.5 °29, and 22.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °20, 14.8 °20, 26.8 °20, 7.3 °20, 13.5 °20, and 22.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.6 °20, 14.8 °20, 26.8 °20, 7.3 °20, 13.5 °20, 22.3 °20, and 14.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °20, 14.8 °20, 26.8 °20, 7.3 °20, 13.5 °20, 22.3 °20, and
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.6 °20, 14.8 °20, 26.8 °20, 7.3 °20, 13.5 °20, 22.3 °20,
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °29, 14.8 °29, 26.8 °29, 7.3 °29,
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.6 °20, 14.8 °20, 26.8 °20, 7.3 °20, 13.5 °20, 22.3 °20,
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °29, 14.8 °29, 26.8 °29, 7.3 °29,
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 25.6 °20, 14.8 °20, 26.8 °20, 7.3 °20, 13.5 °20, 22.3 °20, 14.5 °20, 29.8 °20, 13.8 °20, and 17.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin hydrochloride Pattern B is crystalline ketanserin hydrochloride Pattern B characterized by XRPD signals at 25.6 °29, 14.8 °29, 26.8 °29, 7.3 °29, 13.5 °20, 22.3 °20, 14.5 °20, 29.8 °20, 13.8 °20, and 17.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20;
  • Table 9 is a numerical representation of selected XRPD signals shown in at least Figure 17.
  • the crystalline ketanserin hydrochloride Pattern B is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or twenty-one XRPD signals selected from those set forth in Table 9.
  • the present disclosure provides solid forms of ketanserin sulfate Pattern A, e.g., crystalline forms of ketanserin sulfate Pattern A.
  • the ketanserin sulfate Pattern A XRPD profile is substantially similar to that shown in FIG. 4.
  • the ketanserin sulfate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 136.
  • the ketanserin sulfate Pattern A TGA profile is substantially similar to that shown in FIG. 138.
  • the ketanserin sulfate Pattern A DSC profile is substantially similar to that shown in FIG. 137.
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by an XRPD signal at 23.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °29 and 22.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 23.6 °29, 22.5 °29, and 8.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °29, 22.5 °29, and 8.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °29, 22.5 °29, 8.9 °29, and 16.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °20, 22.5 °20, 8.9 °20, and 16.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, and 25.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °20, 22.5 °20, 8.9 °20, 16.5 °20, and 25.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, 25.0 °29, and 13.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °20, 22.5 °20, 8.9 °20, 16.5 °20, 25.0 °20, and 13.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, 25.0 °29, 13.9 °29, and 21.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °20, 22.5 °20, 8.9 °20, 16.5 °20, 25.0 °20, 13.9 °20, and 21.1 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, 25.0 °29, 13.9 °29, 21.1 °20, and 14.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, 25.0 °29, 13.9 °29, 21.1 °29, and 14.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, 25.0 °29, 13.9 °29, 21.1 °29, 14.9 °29, and 17.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, 25.0 °29, 13.9 °29, 21.1 °29, 14.9 °29, and 17.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, 25.0 °29, 13.9 °29, 21.1 °29, 14.9 °29, 17.4 °29, and 15.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin sulfate Pattern A is crystalline ketanserin sulfate Pattern A characterized by XRPD signals at 23.6 °29, 22.5 °29, 8.9 °29, 16.5 °29, 25.0 °29, 13.9 °29, 21.1 °29, 14.9 °29, 17.4 °29, and 15.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • Table 10 is a numerical representation of selected XRPD signals shown in at least Figure 4.
  • the crystalline ketanserin sulfate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, twenty- four, twenty-five, twenty-six, or twenty-seven XRPD signals selected from those set forth in Table 10.
  • the present disclosure provides solid forms of ketanserin sulfate Pattern B, e.g., crystalline forms of ketanserin sulfate Pattern B.
  • the ketanserin sulfate Pattern B XRPD profile is substantially similar to that shown in FIG. 262.
  • the ketanserin sulfate Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 263.
  • the ketanserin sulfate Pattern B TGA profile is substantially similar to that shown in FIG. 265.
  • the ketanserin sulfate Pattern B DSC profile is substantially similar to that shown in FIG. 264.
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by an XRPD signal at 5.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °20 and 18.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 5.9 °20, 18.9 °20, and 22.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °29, 18.9 °29, and 22.2 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °29, 18.9 °29, 22.2 °29, and 7.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °20, 18.9 °29, 22.2 °29, and 7.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °29, 18.9 °29, 22.2 °29, 7.5 °29, and 18.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °29, 18.9 °29, 22.2 °20, 7.5 °20, and 18.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °29, 18.9 °29, 22.2 °29, 7.5 °29, 18.7 °29, and 14.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °20, 18.9 °20, 22.2 °20, 7.5 °20, 18.7 °20, and 14.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °29, 18.9 °29, 22.2 °29, 7.5 °29, 18.7 °29, 14.3 °29, and
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °20, 18.9 °20, 22.2 °20, 7.5 °20, 18.7 °20, 14.3 °20, and 24.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °29, 18.9 °29, 22.2 °29, 7.5 °29, 18.7 °29, 14.3 °29,
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °29, 18.9 °29, 22.2 °29, 7.5 °29, 18.7 °29, 14.3 °20, 24.3 °20, and 20.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °29, 18.9 °29, 22.2 °29, 7.5 °29, 18.7 °29, 14.3 °29,
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °29, 18.9 °29, 22.2 °29, 7.5 °29, 18.7 °29, 14.3 °20, 24.3 °20, 20.6 °20, and 18.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.9 °29, 18.9 °29, 22.2 °29, 7.5 °29, 18.7 °29, 14.3 °29,
  • the solid form of ketanserin sulfate Pattern B is crystalline ketanserin sulfate Pattern B characterized by XRPD signals at 5.9 °29, 18.9 °29, 22.2 °29, 7.5 °29, 18.7 °29, 14.3 °20, 24.3 °20, 20.6 °20, 18.2 °20, and 16.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the crystalline ketanserin sulfate Pattern B is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, twenty- four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, thirty-one, thirty- two, thirty-three, thirty-four, or thirty-five XRPD signals selected from those set forth in Table 10 A.
  • the present disclosure provides solid forms of ketanserin fumarate Pattern A, e.g., crystalline forms of ketanserin fumarate Pattern A.
  • the ketanserin fumarate Pattern A XRPD profile is substantially similar to that shown in FIG. 5.
  • the ketanserin fumarate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 124.
  • the ketanserin fumarate Pattern A DSC profile is substantially similar to that shown in FIG. 125.
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by an XRPD signal at 24.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °29 and 9.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 24.8 °29, 9.7 °29, and 23.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °29, 9.7 °29, and 23.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °29, 23.1 °29, and 27.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °29, 9.7 °20, 23.1 °20, and 27.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, and 8.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °20, 9.7 °20, 23.1 °20, 27.1 °20, and 8.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, 8.1 °29, and 26.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °20, 9.7 °20, 23.1 °20, 27.1 °20, 8.1 °20, and 26.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, 8.1 °29, 26.0 °29, and 21.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °20, 9.7 °20, 23.1 °20, 27.1 °20, 8.1 °20, 26.0 °20, and 21.0 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, 8.1 °29, 26.0 °29, 21.0 °29, and 16.2 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, 8.1 °29, 26.0 °29, 21.0 °29, and 16.2 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, 8.1 °29, 26.0 °29, 21.0 °29, 16.2 °29, and 23.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, 8.1 °29, 26.0 °29, 21.0 °29, 16.2 °29, and 23.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, 8.1 °29, 26.0 °29, 21.0 °29, 16.2 °29, 23.5 °29, and 17.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin fumarate Pattern A is crystalline ketanserin fumarate Pattern A characterized by XRPD signals at 24.8 °29, 9.7 °29, 23.1 °29, 27.1 °29, 8.1 °29, 26.0 °29, 21.0 °29, 16.2 °29, 23.5 °29, and 17.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • Table 11 is a numerical representation of selected XRPD signals shown in at least Figure 5.
  • the crystalline ketanserin fumarate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, or eighteen XRPD signals selected from those set forth in Table 11.
  • the present disclosure provides solid forms of ketanserin fumarate Pattern B, e.g., crystalline forms of ketanserin fumarate Pattern B.
  • the ketanserin fumarate Pattern B XRPD profile is substantially similar to that shown in FIG. 6.
  • the ketanserin fumarate Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 126.
  • the ketanserin fumarate Pattern B DSC profile is substantially similar to that shown in FIG. 127.
  • the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by an XRPD signal at 15.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by XRPD signals at 15.3 °29 and 9.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °29, 9.6 °29, and 23.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by XRPD signals at 15.3 °29, 9.6 °29, and 23.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 9.6 °29, 23.1 °29, and 3.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by XRPD signals at 15.3 °20, 9.6 °20, 23.1 °20, and 3.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 9.6 °29, 23.1 °29, 3.8 °29, and 19.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by XRPD signals at 15.3 °20, 9.6 °20, 23.1 °20, 3.8 °20, and 19.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 9.6 °29, 23.1 °29, 3.8 °29, 19.1 °29, and 11.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin fumarate Pattern B is crystalline ketanserin fumarate Pattern B characterized by XRPD signals at 15.3 °20, 9.6 °20, 23.1 °20, 3.8 °20, 19.1 °20, and 11.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • Table 12 is a numerical representation of selected XRPD signals shown in at least Figure 6.
  • the crystalline ketanserin fumarate Pattern B is characterized by one, two, three, four, five, or six XRPD signals selected from those set forth in Table 12.
  • the present disclosure provides solid forms of ketanserin citrate Pattern A, e.g., crystalline forms of ketanserin citrate Pattern A.
  • the ketanserin citrate Pattern A XRPD profile is substantially similar to that shown in FIG. 7.
  • the ketanserin citrate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 119.
  • the ketanserin citrate Pattern A DSC profile is substantially similar to that shown in FIG. 120.
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by an XRPD signal at 14.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °29 and 19.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 14.1 °29, 19.8 °29, and 3.5 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °29, 19.8 °29, and 3.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °29, 19.8 °29, 3.5 °29, and 13.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °29, 19.8 °29, 3.5 °20, and 13.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, and 7.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °29, 19.8 °29, 3.5 °20, 13.3 °20, and 7.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, and 22.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °29, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, and 22.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, and 21.0 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, and 21.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, 21.0 °20, and 20.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, 21.0 °20, and 20.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, 21.0 °20, 20.7 °29, and 10.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, 21.0 °20, 20.7 °20, and 10.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, 21.0 °20, 20.7 °20, 10.1 °20, and 15.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin citrate Pattern A is crystalline ketanserin citrate Pattern A characterized by XRPD signals at 14.1 °20, 19.8 °20, 3.5 °20, 13.3 °20, 7.0 °20, 22.7 °20, 21.0 °20, 20.7 °20, 10.1 °20, and 15.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • Table 13 is a numerical representation of selected XRPD signals shown in at least Figure 7.
  • the crystalline ketanserin citrate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen XRPD signals selected from those set forth in Table 13.
  • the present disclosure provides solid forms of ketanserin maleate Pattern A, e.g., crystalline forms of ketanserin maleate Pattern A.
  • the ketanserin maleate Pattern A XRPD profile is substantially similar to that shown in FIG. 8.
  • the ketanserin maleate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 131.
  • the ketanserin maleate Pattern A TGA profile is substantially similar to that shown in FIG. 133.
  • the ketanserin maleate Pattern A DSC profile is substantially similar to that shown in FIG. 132.
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by an XRPD signal at 11.2 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °29 and 26.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 11.2 °29, 26.1 °29, and 24.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °29, 26.1 °29, and 24.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °29, 26.1 °29, 24.3 °29, and 24.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °29, 26.1 °20, 24.3 °20, and 24.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °29, 26.1 °29, 24.3 °29, 24.7 °29, and 25.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, and 25.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °29, 26.1 °29, 24.3 °29, 24.7 °29, 25.7 °29, and 27.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, and 27.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, 27.7 °20, and 15.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, 27.7 °20, and 15.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, 27.7 °20, 15.7 °29, and 9.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, 27.7 °20, 15.7 °20, and 9.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, 27.7 °20, 15.7 °20, 9.1 °20, and 16.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, 27.7 °20, 15.7 °20, 9.1 °20, and 16.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 11.2 °20, 26.1 °20, 24.3 °20, 24.7 °20, 25.7 °20, 27.7 °20, 15.7 °20, 9.1 °20, 16.6 °20, and 22.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin maleate Pattern A is crystalline ketanserin maleate Pattern A characterized by XRPD signals at 11.2 °29, 26.1 °29, 24.3 °29, 24.7 °29, 25.7 °20, 27.7 °20, 15.7 °20, 9.1 °20, 16.6 °20, and 22.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • Table 14 is a numerical representation of selected XRPD signals shown in at least Figure 8.
  • the crystalline ketanserin maleate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, or seventeen XRPD signals selected from those set forth in Table 14.
  • the present disclosure provides solid forms of ketanserin maleate Pattern B, e.g., crystalline forms of ketanserin maleate Pattern B.
  • the ketanserin maleate Pattern B XRPD profile is substantially similar to that shown in FIG. 261.
  • the ketanserin maleate Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 52.
  • the ketanserin maleate Pattern B DSC profile is substantially similar to that shown in FIG. 51.
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by an XRPD signal at 18.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at 18.1 °29 and 8.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 18.1 °29, 8.8 °29, and 6.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at 18.1 °29, 8.8 °29, and 6.0 °29 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.1 °29, 8.8 °29, 6.0 °29, and 17.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at 18.1 °29, 8.8 °20, 6.0 °20, and 17.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, and 26.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, 26.9 °29, and 16.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at 18.1 °20, 8.8 °20, 6.0 °20, 17.6 °20, 26.9 °20, and 16.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, 26.9 °29, 16.6 °29, and
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at 18.1 °20, 8.8 °20, 6.0 °20, 17.6 °20, 26.9 °20, 16.6 °20, and 17.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, 26.9 °29, 16.6 °29,
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, 26.9 °29, 16.6 °29, 17.2 °29, and 13.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, 26.9 °29, 16.6 °29,
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, 26.9 °29, 16.6 °29, 17.2 °29, 13.8 °29, and 23.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, 26.9 °29, 16.6 °29,
  • the solid form of ketanserin maleate Pattern B is crystalline ketanserin maleate Pattern B characterized by XRPD signals at 18.1 °29, 8.8 °29, 6.0 °29, 17.6 °29, 26.9 °29, 16.6 °29, 17.2 °29, 13.8 °29, 23.5 °29, and 21.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the crystalline ketanserin maleate Pattern B is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, or seventeen XRPD signals selected from those set forth in Table 14 A.
  • the present disclosure provides solid forms of ketanserin p- tosylate Pattern A, e.g., crystalline forms of ketanserin p-tosylate Pattern A.
  • the ketanserin p-tosylate Pattern A XRPD profile is substantially similar to that shown in FIG. 9.
  • the ketanserin p-tosylate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 139.
  • the ketanserin p-tosylate Pattern A DSC profile is substantially similar to that shown in FIG. 140.
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by an XRPD signal at 21.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by XRPD signals at 21.8 °29 and 3.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.8 °29, 3.3 °29, and 23.2 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by XRPD signals at 21.8 °29, 3.3 °29, and 23.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °29, 3.3 °29, 23.2 °29, and 21.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin p- tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by XRPD signals at 21.8 °20, 3.3 °20, 23.2 °20, and 21.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, and 10.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by XRPD signals at 21.8 °20, 3.3 °20, 23.2 °20, 21.1 °20, and 10.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, 10.0 °29, and 8.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by XRPD signals at 21.8 °20, 3.3 °20, 23.2 °20, 21.1 °20, 10.0 °20, and 8.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, 10.0 °29, 8.6 °29, and 23.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by XRPD signals at 21.8 °20, 3.3 °20, 23.2 °20, 21.1 °20, 10.0 °20, 8.6 °20, and 23.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, 10.0 °29, 8.6 °29, 23.0 °20, and 27.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p- tosylate Pattern A characterized by XRPD signals at 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, 10.0 °20, 8.6 °20, 23.0 °20, and 27.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, 10.0 °29, 8.6 °29, 23.0 °20, 27.0 °20, and 17.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p- tosylate Pattern A characterized by XRPD signals at 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, 10.0 °20, 8.6 °20, 23.0 °20, 27.0 °20, and 17.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p-tosylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, 10.0 °29, 8.6 °29, 23.0 °20, 27.0 °20, 17.9 °20, and 21.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin p-tosylate Pattern A is crystalline ketanserin p- tosylate Pattern A characterized by XRPD signals at 21.8 °29, 3.3 °29, 23.2 °29, 21.1 °29, 10.0 °20, 8.6 °20, 23.0 °20, 27.0 °20, 17.9 °20, and 21.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • Table 15 is a numerical representation of selected XRPD signals shown in at least Figure 9.
  • the crystalline ketanserin p-tosylate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, twenty- four, twenty-five, twenty-six, twenty-seven, twenty-eight, twenty-nine, or thirty XRPD signals selected from those set forth in Table 15.
  • the present disclosure provides solid forms of ketanserin esylate Pattern A, e.g., crystalline forms of ketanserin esylate Pattern A.
  • the ketanserin esylate Pattern A XRPD profile is substantially similar to that shown in FIG. 10.
  • the ketanserin esylate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 121.
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by an XRPD signal at 20.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °29 and 10.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, and 22.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °29, 10.4 °29, and 22.0 °29 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °29, 10.4 °29, 22.0 °29, and 26.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °29, 10.4 °29, 22.0 °20, and 26.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, and 14.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °29, 10.4 °20, 22.0 °20, 26.0 °20, and 14.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, and 20.3 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, and 20.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, 20.3 °20, and 26.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, 20.3 °20, and 26.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, 20.3 °20, 26.9 °20, and 24.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, 20.3 °20, 26.9 °20, and 24.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, 20.3 °20, 26.9 °20, 24.9 °29, and 13.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, 20.3 °20, 26.9 °20, 24.9 °20, and 13.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 20.9 °20, 10.4 °20, 22.0 °20, 26.0 °20, 14.6 °20, 20.3 °20, 26.9 °20, 24.9 °20, 13.3 °20, and 22.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern A is crystalline ketanserin esylate Pattern A characterized by XRPD signals at 20.9 °29, 10.4 °29, 22.0 °29, 26.0 °29, 14.6 °29, 20.3 °20, 26.9 °20, 24.9 °20, 13.3 °20, and 22.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • Table 16 is a numerical representation of selected XRPD signals shown in at least Figure 10.
  • the crystalline ketanserin esylate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, or ten XRPD signals selected from those set forth in Table 16.
  • the present disclosure provides solid forms of ketanserin esylate Pattern B, e.g., crystalline forms of ketanserin esylate Pattern B.
  • the ketanserin esylate Pattern B XRPD profile is substantially similar to that shown in FIG. 11.
  • the ketanserin esylate Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 122.
  • the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by an XRPD signal at 21.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by XRPD signals at 21.8 °29 and 22.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 21.8 °20, 22.1 °20, and 10.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by XRPD signals at 21.8 °29, 22.1 °29, and 10.9 °29 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °29, 22.1 °29, 10.9 °29, and 24.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by XRPD signals at 21.8 °29, 22.1 °29, 10.9 °20, and 24.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °20, 22.1 °20, 10.9 °20, 24.9 °20, and 26.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by XRPD signals at 21.8 °20, 22.1 °20, 10.9 °20, 24.9 °20, and 26.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.8 °20, 22.1 °20, 10.9 °20, 24.9 °20, 26.5 °20, and 27.1 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern B is crystalline ketanserin esylate Pattern B characterized by XRPD signals at 21.8 °29, 22.1 °29, 10.9 °29, 24.9 °29, 26.5 °29, and 27.1 °29 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • Table 17 is a numerical representation of selected XRPD signals shown in at least Figure 11.
  • the crystalline ketanserin esylate Pattern B is characterized by one, two, three, four, five, or six XRPD signals selected from those set forth in Table 17.
  • the present disclosure provides solid forms of ketanserin esylate Pattern C, e.g., crystalline forms of ketanserin esylate Pattern C.
  • the ketanserin esylate Pattern C XRPD profile is substantially similar to that shown in FIG. 12.
  • the ketanserin esylate Pattern C 1H NMR spectrum is substantially similar to that shown in FIG. 123.
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by an XRPD signal at 10.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °20 and 5.3 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by two or more, or three XRPD signals selected from the group consisting of 10.5 °29, 5.3 °29, and 8.8 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °29, 5.3 °29, and 8.8 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °29, 5.3 °29, 8.8 °29, and 22.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °29, 5.3 °29, 8.8 °29, and 22.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, and 23.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °29, 5.3 °29, 8.8 °29, 22.7 °29, and 23.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, and 14.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °29, 5.3 °29, 8.8 °20, 22.7 °20, 23.8 °20, and 14.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, and 19.8 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, and 19.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, 19.8 °20, and 15.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, 19.8 °20, and 15.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, 19.8 °20, 15.5 °29, and 28.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, 19.8 °20, 15.5 °20, and 28.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, 19.8 °20, 15.5 °20, 28.6 °20, and 7.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin esylate Pattern C is crystalline ketanserin esylate Pattern C characterized by XRPD signals at 10.5 °20, 5.3 °20, 8.8 °20, 22.7 °20, 23.8 °20, 14.2 °20, 19.8 °20, 15.5 °20, 28.6 °20, and 7.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • Table 18 is a numerical representation of selected XRPD signals shown in at least Figure 12.
  • the crystalline ketanserin esylate Pattern C is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen XRPD signals selected from those set forth in Table 18.
  • the present disclosure provides solid forms of ketanserin mesylate Pattern A, e.g., crystalline forms of ketanserin mesylate Pattern A.
  • the ketanserin mesylate Pattern A XRPD profile is substantially similar to that shown in FIG. 13.
  • the ketanserin mesylate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 134.
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by an XRPD signal at 24.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °29 and 23.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 24.0 °20, 23.1 °20, and 27.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °29, 23.1 °29, and 27.6 °29 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.0 °29, 23.1 °29, 27.6 °29, and 22.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °29, 23.1 °20, 27.6 °20, and 22.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.0 °29, 23.1 °29, 27.6 °29, 22.7 °29, and 17.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, and 17.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.0 °29, 23.1 °29, 27.6 °29, 22.7 °29, 17.8 °29, and 11.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, 17.8 °20, and 11.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, 17.8 °20, 11.4 °20, and 14.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, 17.8 °20, 11.4 °20, and 14.9 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, 17.8 °20, 11.4 °20,
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, 17.8 °20, 11.4 °20, 14.9 °20, and 20.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, 17.8 °20, 11.4 °20,
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, 17.8 °20, 11.4 °20, 14.9 °20, 20.3 °20, and 29.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.0 °20, 23.1 °20, 27.6 °20, 22.7 °20, 17.8 °20, 11.4 °20,
  • the solid form of ketanserin mesylate Pattern A is crystalline ketanserin mesylate Pattern A characterized by XRPD signals at 24.0 °29, 23.1 °29, 27.6 °29, 22.7 °29, 17.8 °20, 11.4 °20, 14.9 °20, 20.3 °20, 29.6 °20, and 15.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • Table 19 is a numerical representation of selected XRPD signals shown in at least Figure 13.
  • the crystalline ketanserin mesylate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen XRPD signals selected from those set forth in Table 19.
  • the present disclosure provides solid forms of ketanserin mesylate Pattern B, e.g., crystalline forms of ketanserin mesylate Pattern B.
  • the ketanserin mesylate Pattern B XRPD profile is substantially similar to that shown in FIG. 14.
  • the ketanserin mesylate Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 135.
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by an XRPD signal at 23.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °29 and 27.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 23.1 °29, 27.6 °29, and 23.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °29, 27.6 °29, and 23.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.1 °29, 27.6 °29, 23.9 °29, and 14.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °20, 27.6 °20, 23.9 °20, and 14.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.1 °29, 27.6 °29, 23.9 °29, 14.8 °29, and 23.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, and 23.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.1 °29, 27.6 °29, 23.9 °29, 14.8 °29, 23.6 °29, and 17.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, 23.6 °20, and 17.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, 23.6 °20, 17.7 °20, and 15.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, 23.6 °20, 17.7 °20, and
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, 23.6 °20, 17.7 °20,
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, 23.6 °20, 17.7 °20, 15.8 °20, and 18.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, 23.6 °20, 17.7 °20,
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, 23.6 °20, 17.7 °20, 15.8 °20, 18.9 °20, and 15.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 23.1 °20, 27.6 °20, 23.9 °20, 14.8 °20, 23.6 °20, 17.7 °20,
  • the solid form of ketanserin mesylate Pattern B is crystalline ketanserin mesylate Pattern B characterized by XRPD signals at 23.1 °29, 27.6 °29, 23.9 °29, 14.8 °29, 23.6 °20, 17.7 °20, 15.8 °20, 18.9 °20, 15.5 °20, and 22.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • Table 20 is a numerical representation of selected XRPD signals shown in at least Figure 14.
  • the crystalline ketanserin mesylate Pattern B is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, or twenty-two XRPD signals selected from those set forth in Table 20.
  • the present disclosure provides solid forms of ketanserin besylate Pattern A, e.g., crystalline forms of ketanserin besylate Pattern A.
  • the ketanserin besylate Pattern A XRPD profile is substantially similar to that shown in FIG. 15.
  • the ketanserin besylate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 117.
  • the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by an XRPD signal at 9.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by XRPD signals at 9.6 °29 and 4.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 9.6 °29, 4.8 °29, and 24.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by XRPD signals at 9.6 °29, 4.8 °29, and 24.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.6 °29, 4.8 °29, 24.1 °29, and 17.2 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form ofketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by XRPD signals at 9.6 °29, 4.8 °29, 24.1 °29, and 17.2 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.6 °29, 4.8 °29, 24.1 °29, 17.2 °29, and 22.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by XRPD signals at
  • the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.6 °29, 4.8 °29, 24.1 °29, 17.2 °29, 22.6 °29, and 21.0 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by XRPD signals at 9.6 °20, 4.8 °20, 24.1 °20, 17.2 °20, 22.6 °20, and 21.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 9.6 °29, 4.8 °29, 24.1 °29, 17.2 °29, 22.6 °29, 21.0 °29, and
  • the solid form of ketanserin besylate Pattern A is crystalline ketanserin besylate Pattern A characterized by XRPD signals at 9.6 °20, 4.8 °20, 24.1 °20, 17.2 °20, 22.6 °20, 21.0 °20, and 20.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • Table 21 is a numerical representation of selected XRPD signals shown in at least Figure 15.
  • the crystalline ketanserin besylate Pattern A is characterized by one, two, three, four, five, six, or seven XRPD signals selected from those set forth in Table 21.
  • the present disclosure provides solid forms of ketanserin besylate Pattern B, e.g., crystalline forms of ketanserin besylate Pattern B.
  • the ketanserin besylate Pattern B XRPD profile is substantially similar to that shown in FIG. 16.
  • the ketanserin besylate Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 118.
  • the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by an XRPD signal at 21.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by XRPD signals at 21.7 °29 and 9.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 21.7 °20, 9.9 °20, and 3.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by XRPD signals at 21.7 °29, 9.9 °29, and 3.3 °29 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °29, 9.9 °29, 3.3 °29, and 15.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by XRPD signals at 21.7 °29, 9.9 °20, 3.3 °20, and 15.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °29, 9.9 °29, 3.3 °29, 15.4 °29, and 23.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by XRPD signals at 21.7 °20, 9.9 °29, 3.3 °20, 15.4 °29, and 23.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °29, 9.9 °29, 3.3 °29, 15.4 °29, 23.3 °29, and 6.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by XRPD signals at 21.7 °20, 9.9 °20, 3.3 °20, 15.4 °20, 23.3 °20, and 6.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °29, 9.9 °29, 3.3 °29, 15.4 °29, 23.3 °29, 6.7 °29, and 13.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by XRPD signals at 21.7 °20, 9.9 °20, 3.3 °20, 15.4 °20, 23.3 °20, 6.7 °20, and 13.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °20, 9.9 °20, 3.3 °20, 15.4 °20, 23.3 °20, 6.7 °20, 13.3 °29, and 4.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by XRPD signals at 21.7 °20, 9.9 °20, 3.3 °20, 15.4 °20, 23.3 °20, 6.7 °20, 13.3 °29, and 4.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.7 °20, 9.9 °20, 3.3 °20, 15.4 °20, 23.3 °20, 6.7 °20, 13.3 °29, 4.9 °29, and 20.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin besylate Pattern B is crystalline ketanserin besylate Pattern B characterized by XRPD signals at 21.7 °29, 9.9 °29, 3.3 °29, 15.4 °29, 23.3 °29, 6.7 °29, 13.3 °29, 4.9 °20, and 20.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • Table 22 is a numerical representation of selected XRPD signals shown in at least Figure 16.
  • the crystalline ketanserin besylate Pattern B is characterized by one, two, three, four, five, six, seven, eight, or nine XRPD signals selected from those set forth in Table 22.
  • Solid forms of ketanserin succinate Pattern A the present disclosure provides solid forms of ketanserin succinate
  • the ketanserin succinate Pattern A e.g., crystalline forms of ketanserin succinate Pattern A.
  • the ketanserin succinate Pattern A XRPD profile is substantially similar to that shown in any one of FIGs. 20, 112, or 113.
  • the ketanserin succinate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 177.
  • the ketanserin succinate Pattern A TGA profile is substantially similar to that shown in FIG. 179.
  • the ketanserin succinate Pattern A DSC profile is substantially similar to that shown in FIG. 178.
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by an XRPD signal at 15.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29 and 19.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, and 11.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 19.4 °29, and 11.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 11.5 °29, and 23.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 19.4 °20, 11.5 °20, and 23.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 11.5 °29, 23.0 °29, and 9.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 19.4 °20, 11.5 °20, 23.0 °20, and 9.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 11.5 °29, 23.0 °29, 9.8 °29, and 24.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 19.4 °20, 11.5 °20, 23.0 °20, 9.8 °20, and 24.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 11.5 °29, 23.0 °29, 9.8 °29, 24.6 °29, and 21.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 19.4 °20, 11.5 °20, 23.0 °20, 9.8 °20, 24.6 °20, and
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 11.5 °29, 23.0 °29, 9.8 °29, 24.6 °29,
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 19.4 °29, 11.5 °29, 23.0 °29, 9.8 °29, 24.6 °20, 21.5 °20, and 20.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 11.5 °29, 23.0 °29, 9.8 °29, 24.6 °29,
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 19.4 °29, 11.5 °29, 23.0 °29, 9.8 °29, 24.6 °20, 21.5 °20, 20.8 °20, and 25.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 11.5 °29, 23.0 °29, 9.8 °29, 24.6 °29,
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 19.4 °29, 11.5 °29, 23.0 °29, 9.8 °20, 24.6 °20, 21.5 °20, 20.8 °20, 25.3 °20, and 3.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • Table 23 is a numerical representation of selected XRPD signals shown in at least Figure 20.
  • the crystalline ketanserin succinate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, or eleven XRPD signals selected from those set forth in Table 23.
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by an XRPD signal at 15.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29 and 19.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, and 9.8 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 19.4 °29, and 9.8 °29 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 9.8 °29, and 24.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 19.4 °20, 9.8 °20, and 24.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 9.8 °29, 24.6 °29, and 11.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 9.8 °29, 24.6 °29, 11.5 °29, and 23.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, 11.5 °20, and 23.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 19.4 °29, 9.8 °29, 24.6 °29, 11.5 °29, 23.0 °29, and
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, 11.5 °20, 23.0 °20, and 25.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, 11.5 °20, 23.0 °20, 25.3 °29, and 20.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, 11.5 °20, 23.0 °20, 25.3 °20, and 20.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, 11.5 °20, 23.0 °20, 25.3 °20, 20.8 °20, and 21.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 19.4 °29, 9.8 °29, 24.6 °29, 11.5 °29, 23.0 °20, 25.3 °20, 20.8 °20, and 21.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 19.4 °20, 9.8 °20, 24.6 °20, 11.5 °20, 23.0 °20, 25.3 °20, 20.8 °20, 21.5 °20, and 18.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 19.4 °29, 9.8 °29, 24.6 °29, 11.5 °29, 23.0 °20, 25.3 °20, 20.8 °20, 21.5 °20, and 18.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the crystalline ketanserin succinate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, or fourteen XRPD signals selected from those set forth in Table 24.
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by an XRPD signal at 15.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29 and 23.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 15.3 °20, 23.0 °20, and 11.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 23.0 °29, and 11.5 °29 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 23.0 °29, 11.5 °29, and 19.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 23.0 °20, 11.5 °20, and 19.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 23.0 °29, 11.5 °29, 19.4 °29, and 21.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, and 21.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 23.0 °29, 11.5 °29, 19.4 °29, 21.5 °29, and 9.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, and 9.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °29, 23.0 °29, 11.5 °29, 19.4 °29, 21.5 °29, 9.8 °29, and 21.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, 9.8 °20, and 21.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, 9.8 °20, 21.7 °29, and 25.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, 9.8 °20, 21.7 °20, and 25.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, 9.8 °20, 21.7 °20, 25.0 °20, and 15.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °29, 23.0 °29, 11.5 °29, 19.4 °29, 21.5 °29, 9.8 °20, 21.7 °20, 25.0 °20, and 15.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, 9.8 °20, 21.7 °20, 25.0 °20, 15.0 °20, and 24.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern A is crystalline ketanserin succinate Pattern A characterized by XRPD signals at 15.3 °20, 23.0 °20, 11.5 °20, 19.4 °20, 21.5 °20, 9.8 °20, 21.7 °20, 25.0 °20, 15.0 °20, and 24.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the crystalline ketanserin succinate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, or twelve XRPD signals selected from those set forth in Table 25.
  • the present disclosure provides solid forms of ketanserin succinate Pattern B, e.g., crystalline forms of ketanserin succinate Pattern B.
  • the ketanserin succinate Pattern B XRPD profile is substantially similar to that shown in FIG. 21.
  • the ketanserin succinate Pattern B 1H NMR spectrum is substantially similar to that shown in FIG. 180.
  • the ketanserin succinate Pattern B TGA profile is substantially similar to that shown in FIG. 182.
  • the ketanserin succinate Pattern B DSC profile is substantially similar to that shown in FIG. 181.
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by an XRPD signal at 26.2 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °29 and 20.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by two or more, or three XRPD signals selected from the group consisting of 26.2 °20, 20.0 °20, and 27.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °29, 20.0 °29, and 27.5 °29 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °29, 20.0 °29, 27.5 °29, and 22.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °20, 20.0 °20, 27.5 °20, and 22.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °29, 20.0 °29, 27.5 °29, 22.0 °29, and 18.2 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °20, 20.0 °20, 27.5 °20, 22.0 °20, and 18.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °29, 20.0 °29, 27.5 °29, 22.0 °29, 18.2 °29, and 25.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °20, 20.0 °20, 27.5 °20, 22.0 °20, 18.2 °20, and 25.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °29, 20.0 °29, 27.5 °29, 22.0 °29, 18.2 °29, 25.7 °29, and 31.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °20, 20.0 °20, 27.5 °20, 22.0 °20, 18.2 °20, 25.7 °20, and 31.5 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °29, 20.0 °29, 27.5 °29, 22.0 °29, 18.2 °29, 25.7 °29, 31.5 °29, and 8.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °20, 20.0 °20, 27.5 °20, 22.0 °20, 18.2 °20, 25.7 °20, 31.5 °20, and 8.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °29, 20.0 °29, 27.5 °29, 22.0 °29, 18.2 °29, 25.7 °29, 31.5 °20, 8.7 °20, and 20.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °29, 20.0 °29, 27.5 °29, 22.0 °29, 18.2 °29, 25.7 °20, 31.5 °20, 8.7 °20, and 20.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.2 °29, 20.0 °29, 27.5 °29, 22.0 °29, 18.2 °29, 25.7 °29, 31.5 °20, 8.7 °20, 20.4 °20, and 16.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern B is crystalline ketanserin succinate Pattern B characterized by XRPD signals at 26.2 °29, 20.0 °29, 27.5 °29, 22.0 °29, 18.2 °20, 25.7 °20, 31.5 °20, 8.7 °20, 20.4 °20, and 16.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • Table 26 is a numerical representation of selected XRPD signals shown in at least Figure 21.
  • the crystalline ketanserin succinate Pattern B is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, or twenty-two XRPD signals selected from those set forth in Table 26.
  • the present disclosure provides solid forms of ketanserin succinate Pattern C, e.g., crystalline forms of ketanserin succinate Pattern C.
  • the ketanserin succinate Pattern C XRPD profile is substantially similar to that shown in FIGs. 22 or 115.
  • the ketanserin succinate Pattern C 1H NMR spectrum is substantially similar to that shown in FIG. 183.
  • the ketanserin succinate Pattern C TGA profile is substantially similar to that shown in FIG. 185.
  • the ketanserin succinate Pattern C DSC profile is substantially similar to that shown in FIG. 184.
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by an XRPD signal at 19.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29 and 26.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three XRPD signals selected from the group consisting of 19.8 °29, 26.4 °29, and 15.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29, 26.4 °29, and 15.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 26.4 °29, 15.1 °29, and 25.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29, 26.4 °20, 15.1 °20, and 25.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 26.4 °29, 15.1 °29, 25.0 °29, and 9.9 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 26.4 °29, 15.1 °29, 25.0 °29, 9.9 °29, and 15.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °20, 26.4 °20, 15.1 °20, 25.0 °20, 9.9 °20, and 15.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 26.4 °29, 15.1 °29, 25.0 °29, 9.9 °29, 15.0 °29, and
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °20, 26.4 °20, 15.1 °20, 25.0 °20, 9.9 °20, 15.0 °20, and 15.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 26.4 °29, 15.1 °29, 25.0 °29, 9.9 °29, 15.0 °29, 15.9 °29, and 22.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °20, 26.4 °20, 15.1 °20, 25.0 °20, 9.9 °20, 15.0 °20, 15.9 °20, and 22.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 26.4 °29, 15.1 °29, 25.0 °29, 9.9 °29, 15.0 °29, 15.9 °20, 22.4 °20, and 18.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29, 26.4 °29, 15.1 °29, 25.0 °29, 9.9 °29, 15.0 °20, 15.9 °20, 22.4 °20, and 18.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 26.4 °29, 15.1 °29, 25.0 °29, 9.9 °29, 15.0 °29, 15.9 °20, 22.4 °20, 18.1 °20, and 16.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29, 26.4 °29, 15.1 °29, 25.0 °29, 9.9 °29, 15.0 °20, 15.9 °20, 22.4 °20, 18.1 °20, and 16.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the crystalline ketanserin succinate Pattern C is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty XRPD signals selected from those set forth in Table 27.
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by an XRPD signal at 19.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29 and 9.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three XRPD signals selected from the group consisting of 19.8 °29, 9.9 °29, and 25.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29, 9.9 °29, and 25.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 9.9 °29, 25.0 °29, and 26.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °20, 9.9 °20, 25.0 °20, and 26.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, and 10.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °20, 9.9 °20, 25.0 °20, 26.4 °20, and 10.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, 10.1 °29, and 15.2 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °20, 9.9 °20, 25.0 °20, 26.4 °20, 10.1 °20, and 15.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, 10.1 °29, 15.2 °29, and 27.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °20, 9.9 °20, 25.0 °20, 26.4 °20, 10.1 °20, 15.2 °20, and 27.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, 10.1 °29, 15.2 °29, 27.9 °20, and 13.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, 10.1 °29, 15.2 °20, 27.9 °20, and 13.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, 10.1 °29, 15.2 °29, 27.9 °29, 13.3 °29, and 16.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, 10.1 °29, 15.2 °29, 27.9 °29, 13.3 °29, and 16.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by two or more, or three or more XRPD signals selected from the group consisting of 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, 10.1 °29, 15.2 °29, 27.9 °29, 13.3 °29, 16.3 °29, and 24.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern C is crystalline ketanserin succinate Pattern C characterized by XRPD signals at 19.8 °29, 9.9 °29, 25.0 °29, 26.4 °29, 10.1 °29, 15.2 °29, 27.9 °29, 13.3 °29, 16.3 °29, and 24.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • Table 27A is a numerical representation of selected XRPD signals shown in at least Figure 22.
  • the crystalline ketanserin succinate Pattern C is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, twenty- four, twenty-five, or twenty-six XRPD signals selected from those set forth in Table 27A.
  • the present disclosure provides solid forms of ketanserin succinate Pattern D, e.g., crystalline forms of ketanserin succinate Pattern D.
  • the ketanserin succinate Pattern D XRPD profile is substantially similar to that shown in FIG. 23.
  • the ketanserin succinate Pattern D 1H NMR spectrum is substantially similar to that shown in FIG. 186.
  • the ketanserin succinate Pattern D TGA profile is substantially similar to that shown in FIG. 188.
  • the ketanserin succinate Pattern D DSC profile is substantially similar to that shown in FIG. 187.
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by an XRPD signal at 5.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °29 and 26.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by two or more, or three XRPD signals selected from the group consisting of 5.0 °29, 26.7 °29, and 27.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °29, 26.7 °29, and 27.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °29, 26.7 °29, 27.5 °29, and 9.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °20, 26.7 °20, 27.5 °20, and 9.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °29, 26.7 °29, 27.5 °29, 9.9 °29, and 21.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °20, 26.7 °20, 27.5 °20, 9.9 °20, and 21.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °29, 26.7 °29, 27.5 °29, 9.9 °29, 21.7 °29, and 10.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °20, 26.7 °20, 27.5 °20, 9.9 °20, 21.7 °20, and 10.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °29, 26.7 °29, 27.5 °29, 9.9 °29, 21.7 °29, 10.9 °29, and
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °20, 26.7 °20, 27.5 °20, 9.9 °20, 21.7 °20, 10.9 °20, and 14.7 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °29, 26.7 °29, 27.5 °29, 9.9 °29, 21.7 °29, 10.9 °29,
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °20, 26.7 °20, 27.5 °20, 9.9 °20, 21.7 °20, 10.9 °20, 14.7 °20, and 8.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °29, 26.7 °29, 27.5 °29, 9.9 °29, 21.7 °29, 10.9 °29,
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °29, 26.7 °29, 27.5 °29, 9.9 °29, 21.7 °29, 10.9 °20, 14.7 °20, 8.7 °20, and 4.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by two or more, or three or more XRPD signals selected from the group consisting of 5.0 °29, 26.7 °29, 27.5 °29, 9.9 °29, 21.7 °29, 10.9 °29,
  • the solid form of ketanserin succinate Pattern D is crystalline ketanserin succinate Pattern D characterized by XRPD signals at 5.0 °29, 26.7 °29, 27.5 °29, 9.9 °29, 21.7 °20, 10.9 °20, 14.7 °20, 8.7 °20, 4.4 °20, and 16.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • Table 28 is a numerical representation of selected XRPD signals shown in at least Figure 23.
  • the crystalline ketanserin succinate Pattern D is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, twenty- four, twenty -five, twenty-six, twenty-seven, twenty-eight, twenty-nine, thirty, or thirty-one XRPD signals selected from those set forth in Table 28.
  • the present disclosure provides solid forms of ketanserin succinate Pattern E, e.g., crystalline forms of ketanserin succinate Pattern E.
  • the ketanserin succinate Pattern E XRPD profile is substantially similar to that shown in FIG. 24.
  • the ketanserin succinate Pattern E 1H NMR spectrum is substantially similar to that shown in FIG. 189.
  • the ketanserin succinate Pattern E TGA profile is substantially similar to that shown in FIG. 191.
  • the ketanserin succinate Pattern E DSC profile is substantially similar to that shown in FIG. 190.
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by an XRPD signal at 14.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °29 and 21.0 °29 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by two or more, or three XRPD signals selected from the group consisting of 14.9 °29, 21.0 °29, and 4.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °29, 21.0 °29, and 4.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 21.0 °29, 4.7 °29, and 22.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °20, 21.0 °20, 4.7 °20, and 22.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 21.0 °29, 4.7 °29, 22.3 °29, and 11.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °20, 21.0 °20, 4.7 °20, 22.3 °20, and 11.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 21.0 °29, 4.7 °29, 22.3 °29, 11.1 °29, and 7.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °20, 21.0 °20, 4.7 °20, 22.3 °20, 11.1 °20, and 7.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 21.0 °29, 4.7 °29, 22.3 °29, 11.1 °29, 7.4 °29, and 8.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °20, 21.0 °20, 4.7 °20, 22.3 °20, 11.1 °20, 7.4 °20, and 8.8 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 21.0 °20, 4.7 °20, 22.3 °20, 11.1 °20, 7.4 °20, 8.8 °29, and 9.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °29, 21.0 °29, 4.7 °29, 22.3 °29, 11.1 °29, 7.4 °29, 8.8 °29, and 9.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 21.0 °29, 4.7 °29, 22.3 °29, 11.1 °29, 7.4 °29, 8.8 °29, 9.4 °29, and 21.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °29, 21.0 °29, 4.7 °29, 22.3 °29, 11.1 °29, 7.4 °29, 8.8 °29, 9.4 °29, and 21.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by two or more, or three or more XRPD signals selected from the group consisting of 14.9 °29, 21.0 °29, 4.7 °29, 22.3 °29, 11.1 °29, 7.4 °29, 8.8 °29, 9.4 °29, 21.3 °29, and 4.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern E is crystalline ketanserin succinate Pattern E characterized by XRPD signals at 14.9 °29, 21.0 °29, 4.7 °29, 22.3 °29, 11.1 °29, 7.4 °29, 8.8 °29, 9.4 °29, 21.3 °29, and 4.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • Table 29 is a numerical representation of selected XRPD signals shown in at least Figure 24.
  • the crystalline ketanserin succinate Pattern E is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or twenty-one XRPD signals selected from those set forth in Table 29.
  • the present disclosure provides solid forms of ketanserin succinate Pattern F, e.g., crystalline forms of ketanserin succinate Pattern F.
  • the ketanserin succinate Pattern F XRPD profile is substantially similar to that shown in FIG. 25.
  • the ketanserin succinate Pattern F 1H NMR spectrum is substantially similar to that shown in FIG. 192.
  • the ketanserin succinate Pattern F TGA profile is substantially similar to that shown in FIG. 194.
  • the ketanserin succinate Pattern F DSC profile is substantially similar to that shown in FIG. 193.
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by an XRPD signal at 26.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °29 and 26.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by two or more, or three XRPD signals selected from the group consisting of 26.9 °29, 26.5 °29, and 14.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °29, 26.5 °29, and 14.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.9 °29, 26.5 °29, 14.8 °29, and 23.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °20, 26.5 °20, 14.8 °20, and 23.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.9 °29, 26.5 °29, 14.8 °29, 23.6 °29, and 12.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °20, 26.5 °20, 14.8 °20, 23.6 °20, and 12.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.9 °29, 26.5 °29, 14.8 °29, 23.6 °29, 12.1 °29, and 16.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °20, 26.5 °20, 14.8 °20, 23.6 °20, 12.1 °20, and 16.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.9 °29, 26.5 °29, 14.8 °29, 23.6 °29, 12.1 °29, 16.9 °29, and 4.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °20, 26.5 °20, 14.8 °20, 23.6 °20, 12.1 °20, 16.9 °20, and 4.5 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.9 °29, 26.5 °29, 14.8 °29, 23.6 °29, 12.1 °29, 16.9 °29,
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °20, 26.5 °20, 14.8 °20, 23.6 °20, 12.1 °20, 16.9 °20, 4.5 °20, and 16.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.9 °29, 26.5 °29, 14.8 °29, 23.6 °29, 12.1 °29, 16.9 °29,
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °29, 26.5 °29, 14.8 °29, 23.6 °29, 12.1 °29, 16.9 °20, 4.5 °20, 16.6 °20, and 25.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by two or more, or three or more XRPD signals selected from the group consisting of 26.9 °29, 26.5 °29, 14.8 °29, 23.6 °29, 12.1 °29, 16.9 °29,
  • the solid form of ketanserin succinate Pattern F is crystalline ketanserin succinate Pattern F characterized by XRPD signals at 26.9 °29, 26.5 °29, 14.8 °29, 23.6 °29, 12.1 °20, 16.9 °20, 4.5 °20, 16.6 °20, 25.0 °20, and 10.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • Table 30 is a numerical representation of selected XRPD signals shown in at least Figure 25.
  • the crystalline ketanserin succinate Pattern F is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, twenty-one, twenty -two, twenty -three, twenty- four, twenty -five, twenty-six, twenty-seven, twenty-eight, or twenty-nine XRPD signals selected from those set forth in Table 30.
  • the present disclosure provides solid forms of ketanserin succinate Pattern G, e.g., crystalline forms of ketanserin succinate Pattern G.
  • the ketanserin succinate Pattern G XRPD profile is substantially similar to that shown in FIG. 26.
  • the ketanserin succinate Pattern G 1H NMR spectrum is substantially similar to that shown in FIG. 195.
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by an XRPD signal at 21.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °29 and 21.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by two or more, or three XRPD signals selected from the group consisting of 21.0 °29, 21.8 °29, and 11.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °29, 21.8 °29, and 11.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 21.8 °29, 11.1 °29, and 5.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °20, 21.8 °20, 11.1 °20, and 5.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 21.8 °29, 11.1 °29, 5.0 °29, and 10.0 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °20, 21.8 °20, 11.1 °20, 5.0 °20, and 10.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 21.8 °29, 11.1 °29, 5.0 °29, 10.0 °29, and 20.2 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °20, 21.8 °20, 11.1 °20, 5.0 °20, 10.0 °20, and 20.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 21.8 °29, 11.1 °29, 5.0 °29, 10.0 °29, 20.2 °29, and 27.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °20, 21.8 °20, 11.1 °20, 5.0 °20, 10.0 °20, 20.2 °20, and 27.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 21.8 °29, 11.1 °29, 5.0 °29, 10.0 °29, 20.2 °29, 27.7 °20, and 26.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °20, 21.8 °20, 11.1 °20, 5.0 °20, 10.0 °20, 20.2 °20, 27.7 °20, and 26.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 21.8 °29, 11.1 °29, 5.0 °29, 10.0 °29, 20.2 °29, 27.7 °20, 26.9 °20, and 18.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °20, 21.8 °20, 11.1 °20, 5.0 °20, 10.0 °20, 20.2 °20, 27.7 °20, 26.9 °20, and 18.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.0 °29, 21.8 °29, 11.1 °29, 5.0 °29, 10.0 °29, 20.2 °29, 27.7 °20, 26.9 °20, 18.9 °20, and 10.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern G is crystalline ketanserin succinate Pattern G characterized by XRPD signals at 21.0 °29, 21.8 °29, 11.1 °29, 5.0 °29, 10.0 °20, 20.2 °20, 27.7 °20, 26.9 °20, 18.9 °20, and 10.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • Table 31 is a numerical representation of selected XRPD signals shown in at least Figure 26.
  • the crystalline ketanserin succinate Pattern G is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen XRPD signals selected from those set forth in Table 31.
  • the present disclosure provides solid forms of ketanserin succinate Pattern H, e.g., crystalline forms of ketanserin succinate Pattern H.
  • the ketanserin succinate Pattern H XRPD profile is substantially similar to that shown in FIG. 27.
  • the ketanserin succinate Pattern H 1H NMR spectrum is substantially similar to that shown in FIG. 196.
  • the ketanserin succinate Pattern H TGA profile is substantially similar to that shown in FIG. 198.
  • the ketanserin succinate Pattern H DSC profile is substantially similar to that shown in FIG. 197.
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by an XRPD signal at 24.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °29 and 23.1 °29 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by two or more, or three XRPD signals selected from the group consisting of 24.9 °29, 23.1 °29, and 27.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °29, 23.1 °29, and 27.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °29, 23.1 °29, 27.1 °29, and 9.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °20, 23.1 °20, 27.1 °20, and 9.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °29, 23.1 °29, 27.1 °29, 9.7 °29, and 25.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, and 25.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °29, 23.1 °29, 27.1 °29, 9.7 °29, 25.9 °29, and 10.8 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, and 10.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20, and 13.2 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20, and 13.2 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20,
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20, 13.2 °20, and 17.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20,
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20, 13.2 °20, 17.7 °20, and 20.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by two or more, or three or more XRPD signals selected from the group consisting of 24.9 °20, 23.1 °20, 27.1 °20, 9.7 °20, 25.9 °20, 10.8 °20,
  • the solid form of ketanserin succinate Pattern H is crystalline ketanserin succinate Pattern H characterized by XRPD signals at 24.9 °29, 23.1 °29, 27.1 °29, 9.7 °29, 25.9 °20, 10.8 °20, 13.2 °20, 17.7 °20, 20.8 °20, and 17.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • Table 32 is a numerical representation of selected XRPD signals shown in at least Figure 27.
  • the crystalline ketanserin succinate Pattern H is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, or thirteen XRPD signals selected from those set forth in Table 32.
  • the present disclosure provides solid forms of ketanserin L-tartrate Pattern A, e.g., crystalline forms of ketanserin L-tartrate Pattern A.
  • the ketanserin L-tartrate Pattern A XRPD profile is substantially similar to that shown in any one of FIGs. 18, 61, or 110.
  • the ketanserin L-tartrate Pattern A 1H NMR spectrum is substantially similar to that shown in FIG. 199.
  • the ketanserin L-tartrate Pattern A TGA profile is substantially similar to that shown in FIG. 201.
  • the ketanserin L-tartrate Pattern A DSC profile is substantially similar to that shown in FIG. 200.
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by an XRPD signal at 21.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °29 and 13.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, and 15.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °29, 13.9 °20, and 15.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 15.6 °29, and 21.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L- tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 15.6 °20, and 21.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 15.6 °29, 21.7 °29, and 25.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, and 25.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 15.6 °29, 21.7 °29, 25.3 °29, and 16.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, 25.3 °20, and 16.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 15.6 °29, 21.7 °29, 25.3 °29, 16.6 °29, and 15.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, 25.3 °20, 16.6 °20, and
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, 25.3 °20, 16.6 °20,
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, 25.3 °20, 16.6 °20, 15.1 °20, and 12.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, 25.3 °20, 16.6 °20,
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, 25.3 °20, 16.6 °20, 15.1 °20, 12.6 °20, and 20.9 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, 25.3 °20, 16.6 °20,
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L- tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 15.6 °20, 21.7 °20, 25.3 °20, 16.6 °20, 15.1 °20, 12.6 °20, 20.9 °20, and 7.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • Table 33 is a numerical representation of selected XRPD signals shown in at least Figure 18.
  • the crystalline ketanserin L-tartrate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty XRPD signals selected from those set forth in Table 33.
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by an XRPD signal at 21.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °29 and 13.9 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, and 25.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °29, 13.9 °20, and 25.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 25.3 °29, and 15.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L- tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 25.3 °20, and 15.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 25.3 °29, 15.6 °29, and 16.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 25.3 °20, 15.6 °20, and 16.6 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 25.3 °29, 15.6 °29, 16.6 °29, and 15.1 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 25.3 °20, 15.6 °20, 16.6 °20, and 15.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 25.3 °29, 15.6 °29, 16.6 °29, 15.1 °29, and 12.7 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 25.3 °20, 15.6 °20, 16.6 °20, 15.1 °20, and
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 25.3 °29, 15.6 °29, 16.6 °29, 15.1 °29,
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 25.3 °20, 15.6 °20, 16.6 °20, 15.1 °20, 12.7 °20, and 21.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 25.3 °29, 15.6 °29, 16.6 °29, 15.1 °29,
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 13.9 °20, 25.3 °20, 15.6 °20, 16.6 °20, 15.1 °20, 12.7 °20, 21.0 °20, and 22.3 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 13.9 °29, 25.3 °29, 15.6 °29, 16.6 °29, 15.1 °29,
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L- tartrate Pattern A characterized by XRPD signals at 21.6 °29, 13.9 °29, 25.3 °29, 15.6 °29, 16.6 °20, 15.1 °20, 12.7 °20, 21.0 °20, 22.3 °20, and 18.7 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the crystalline ketanserin L-tartrate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, or twenty XRPD signals selected from those set forth in Table 34.
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by an XRPD signal at 21.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °29 and 15.6 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three XRPD signals selected from the group consisting of 21.6 °20, 15.6 °20, and 14.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °29, 15.6 °29, and 14.8 °29 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 15.6 °29, 14.8 °29, and 12.4 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °29, 15.6 °20, 14.8 °20, and 12.4 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 15.6 °29, 14.8 °29, 12.4 °29, and 20.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 15.6 °20, 14.8 °20, 12.4 °20, and 20.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 15.6 °29, 14.8 °29, 12.4 °29, 20.5 °29, and 17.5 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 15.6 °20, 14.8 °20, 12.4 °20, 20.5 °20, and 17.5 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 15.6 °29, 14.8 °29, 12.4 °29, 20.5 °29, 17.5 °29, and 25.3 °29 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kai radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 15.6 °20, 14.8 °20, 12.4 °20, 20.5 °20, 17.5 °20, and 25.3 °20 ( ⁇ 0.2 °29; ⁇ 0.1 °29; or ⁇ 0.0 °29; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 15.6 °29, 14.8 °29, 12.4 °29, 20.5 °29, 17.5 °29,
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °20, 15.6 °20, 14.8 °20, 12.4 °20, 20.5 °20, 17.5 °20, 25.3 °20, and 7.8 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 15.6 °29, 14.8 °29, 12.4 °29, 20.5 °29, 17.5 °29,
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by XRPD signals at 21.6 °29, 15.6 °29, 14.8 °29, 12.4 °29, 20.5 °29, 17.5 °20, 25.3 °20, 7.8 °20, and 21.1 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L-tartrate Pattern A characterized by two or more, or three or more XRPD signals selected from the group consisting of 21.6 °29, 15.6 °29, 14.8 °29, 12.4 °29, 20.5 °29, 17.5 °29,
  • the solid form of ketanserin L-tartrate Pattern A is crystalline ketanserin L- tartrate Pattern A characterized by XRPD signals at 21.6 °29, 15.6 °29, 14.8 °29, 12.4 °29, 20.5 °20, 17.5 °20, 25.3 °20, 7.8 °20, 21.1 °20, and 17.0 °20 ( ⁇ 0.2 °20; ⁇ 0.1 °20; or ⁇ 0.0 °20; Cu Kal radiation).
  • Table 35 is a numerical representation of selected XRPD signals shown in at least Figure 61.
  • the crystalline ketanserin L-tartrate Pattern A is characterized by one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, or sixteen XRPD signals selected from those set forth in Table 35.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La divulgation concerne des formes de kétansérine, comprenant des formes solides de base libre de kétansérine, des sels de kétansérine et leurs formes solides, comprenant des formes cristallines du composé et ses sels, ainsi que des polymorphes des formes solides.
PCT/US2022/082488 2021-12-29 2022-12-28 Sel et formes solides de kétansérine Ceased WO2023129976A1 (fr)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US202163294581P 2021-12-29 2021-12-29
US202163294746P 2021-12-29 2021-12-29
US63/294,581 2021-12-29
US63/294,746 2021-12-29
US202263306927P 2022-02-04 2022-02-04
US63/306,927 2022-02-04
US202263326771P 2022-04-01 2022-04-01
US63/326,771 2022-04-01
US202263357622P 2022-06-30 2022-06-30
US63/357,622 2022-06-30
US202263412306P 2022-09-30 2022-09-30
US63/412,306 2022-09-30

Publications (1)

Publication Number Publication Date
WO2023129976A1 true WO2023129976A1 (fr) 2023-07-06

Family

ID=87000317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/082488 Ceased WO2023129976A1 (fr) 2021-12-29 2022-12-28 Sel et formes solides de kétansérine

Country Status (1)

Country Link
WO (1) WO2023129976A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12295959B2 (en) 2021-12-15 2025-05-13 Delix Therapeutics, Inc. Phenoxy and benzyloxy substituted psychoplastogens and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
CN109836411A (zh) * 2017-11-25 2019-06-04 辽宁博美医药科技有限公司 一种心血管药物酮舍林酒石酸的制备方法
US20200352947A1 (en) * 2017-11-01 2020-11-12 National University Of Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
US20200352947A1 (en) * 2017-11-01 2020-11-12 National University Of Singapore Use of serotonergic drugs to treat virus-induced thrombocytopenia
CN109836411A (zh) * 2017-11-25 2019-06-04 辽宁博美医药科技有限公司 一种心血管药物酮舍林酒石酸的制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12295959B2 (en) 2021-12-15 2025-05-13 Delix Therapeutics, Inc. Phenoxy and benzyloxy substituted psychoplastogens and uses thereof

Similar Documents

Publication Publication Date Title
US12157723B2 (en) Compounds
US20230285356A1 (en) Nonracemic mixtures and uses thereof
US12318390B2 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
KR20220080119A (ko) 선택적 칼륨 채널 조절제의 고체 상태 결정성 형태
US20240409526A1 (en) Phenethylamine compounds salts, polymorphic forms and methods of use thereof
US20240336566A1 (en) Crystalline forms of a compound for the targeted degradation of the androgen receptor
WO2023129976A1 (fr) Sel et formes solides de kétansérine
TW200824689A (en) Novel compounds
WO2023107966A1 (fr) Formes salines et solides du diéthylamide de l'acide lysergique (lsd) et analogues
TW201630902A (zh) 化合物、組合物及方法
TW201940168A (zh) 含代謝性麩胺酸性受體第２亞型之正別構調節劑或正位激動劑之組合及其用途（二）
US20250206720A1 (en) Solid forms of an ulk inhibitor
EP4568667A2 (fr) Sels d'inhibiteurs hétérocycliques du transporteur 4 de monocarboxylate pour le traitement d'une maladie
EP2332529A1 (fr) Diamines aromatiques substituées en tant que ligands des transporteurs de glutamate vésiculaires 1 et 2 (vGLUT1 et vGLUT2)
EA049402B1 (ru) Соединения
HK40060666A (en) Method of synthesis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22917541

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 24/10/2024).

122 Ep: pct application non-entry in european phase

Ref document number: 22917541

Country of ref document: EP

Kind code of ref document: A1